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A     adenine 
Amp     ampicillin 
aa      amino acid  
AOM      azoxymethane 
bp     basepair 
BSA     bovine serum albumin 
C     cytosine or celsius 
CNTF     ciliary neurotrophic factor 
cDNA     complementary DNA 
cm     centimeter 
cm2      square centimeter 
Da     dalton 
DMSO     dimethl sulfoxide 
DNA     desoxyribonucleic acid 
dNTP     desoxynucleotide triphosphate 
E.coli      Escherichia coli 
FACS     fluorescence activated cell sorting 
FCS      fetal calf serum 
Fig     figure 
G     guanine 
g     gram or gravity 
H2SO4     sulfuric acid 
IgG     immunglobulin G 
IL     interleukin 
IL-6R     interleukin-6 receptor 
JAK      janus kinase 
LBamp     LB medium with 50 µg/ml ampicillin 
l     liter 
LIF      leukemia-inhibitory factor 
LIFR      LIF receptor 
M     molar 
m     murine 
mA     milliampère 
µg     microgram 
Abbreviation v 
µl     microliter 
µM     micromolar 
mg     milligram   
ml     milliliter 
mM     millimolar 
min     minute 
NaOH     sodium hydroxide 
ng     nanogram 
nm     nanometer 
PE     phycoerythrin 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction  
pH     pH (potentia Hydrogenii)-value 
P/S      penicillin/streptomycin 
RNA     ribonucleic acid 
RNase    ribonuclease 
rpm     rounds per minute 
RT     room temperature 
SDS     sodium dodecyl sulfate 
sec     second(s) 
sIL-6R     soluble interleukin-6 receptor 
sgp130Fc     soluble gp130Fc 
T     thymine 
Tab.     table 
Taq     Thermophilus aquaticus 
TEMED    N,N,N´,N´- tetramethylethylenediamine 
TM     primer-annealing temperature 
TNF        tumor necrosis factor 
Tris     tris-(Hydroxymethyl)-aminomethane 
tRNA     transfer RNA 
U     unit(s)  
V     volt 
v/v     volume per volume 




1.1 Interleukin-6 and the gp130 cytokine family 
Cytokines are small soluble proteins, which are secreted by and act on a variety of 
different cell types. They are grouped into different families based on structural 
features. The Interleukin-6 family cytokines are characterized by four α-helices. They 
comprise of Interleukin-6 (IL-6), Interleukin-11 (IL-11), Interleukin-27 (IL-27), 
Interleukin-31 (IL-31), ciliary’s neurotrophic factor (CNTF), leukemia inhibitory factor 
(LIF), oncostatin M (OSM), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC) 
and neuropoietin (NPN) (Taga and Kishimoto 1997; Derouet et al. 2004; Dillon et al. 
2004; Pflanz et al. 2004). IL-6 type cytokines bind to plasma membrane receptor 
complexes containing the common signal transducing protein gp130. gp130 as well 
as LIFR and OSMR are ß-receptors and activated through binding of their cytokine 
ligands. Some cytokines such as IL-6, IL-11, LIF, CLC or CNTF first bind to their 
specific α-receptor before binding to gp130 which finally activates the e.g. IL-6 
specific signal. Signal transduction involves activation of JAK (Janus kinase) tyrosine 
kinase family members, leading to activation of STAT (signal tranducers and 
activators of transcription) transcription factors or activation of MAPK (mitogen-
activated protein kinase) cascade. All cytokines of this family can activate target 
genes which are involved in differentiation, survival, apoptosis and proliferation, have 
pro- as well as anti-inflammatory properties and play major roles in hematopoiesis, 
acute phase response and immune responses of the organism (Heinrich et al. 2003).  
The first identified cytokine of the Interleukin-6 family is IL-6 itself. It is a pleiotropic 
cytokine and was originally isolated as B cell differentiation factor (BSF-2) that 
induced final maturation of B cells into antibody producing cells (Hirano et al. 1985; 
Hirano et al. 1986). IL-6 plays a central role in differentiation and growth of different 
cell types as for example keratinocytes, macrophages, B cells, T cells or neuronal 
cells. Moreover, IL-6 induces expression of various acute phase response genes, 
acts as hepatocyte stimulating factor and is important for the maintenance of 
numerous inflammatory diseases such as Crohn’s disease, Castleman’s disease, 
osteoporosis, sepsis or rheumatoid arthritis (Naka et al. 2002).  
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1.2 Interleukin-6 signaling 
On target cells IL-6 first binds to the Interleukin-6 receptor α (IL-6Rα). The complex of 
IL-6 and IL-6Rα associates with gp130 which dimerizes and initiates intracellular 
signaling (Fig. 1-1 A, Taga and Kishimoto 1997; Heinrich et al. 1998). Almost all cells 
express gp130, but IL-6Rα is only present on some cells including hepatocytes, 
neutrophils, monocytes, macrophages and T-lymphocytes. This so-called classic 
signaling pathway is activated during early inflammation as well as infection 
responses and leads to the expression of different acute-phase proteins. A soluble 
form of the IL-6R (sIL-6R) can be generated by differential splicing or proteolytic 
cleavage of membrane-anchored IL-6R by the metalloproteases A Disintegrin And 
Metalloprotease 10 (ADAM10) or ADAM17, also known as TNF-α converting enzyme 
(TACE, Lust et al. 1992; Rose-John and Heinrich 1994; Mullberg et al. 2000). sIL-6R 
together with IL-6 forms a complex which directly binds to gp130 and activates 














Fig. 1-1: The different IL-6 signaling pathways (A) Classic IL-6 signaling, (B) IL-6 trans-signaling, 




This pathway, termed trans-signaling, can stimulate cells which only express gp130 
and lack the α-receptor. However, activity of the IL-6/sIL-6R complex is limited by the 
presence of a soluble form of gp130 (sgp130). Soluble gp130 can compete with 
membrane-bound gp130 for binding to IL-6/sIL-6R complex (Fig. 1-1 C). Therefore, 
sgp130 inhibits IL-6 trans-signaling but not the classical pathway (Muller-Newen et al. 
1998; Jostock et al. 2001). IL-6 trans-signaling plays a key role in the 
pathophysiology of chronic inflammatory disorders and several types of cancer 
(Rose-John and Heinrich 1994; Peters et al. 1998; Mullberg et al. 2000). 
In both pathways ligand-induced dimerization of gp130 leads to autophosphorylation 
of JAK kinases which stimulates the phosphorylation of five tyrosine residues of 
gp130. This subsequently induces recruitment of signaling proteins via SH2 domains, 
such as SHP2 (Src homology 2-containing tyrosine phosphatase) or STAT1 and 
STAT3 (signal transducers and activators of transcription 1 and 3). Upon 
phosphorylation, STAT1 or STAT3 dimerize and translocate into the nucleus to 
induce expression of IL-6 target genes. Alternatively, SHP-2 is phosphorylated and 
activates the Ras-Raf-MAPK signaling pathway via its interaction with the 
GRB2/SOS (Growth factor receptor-bound protein 2/Son of Sevenless) complex 
which finally induces expression of gp130 target genes (Holgado-Madruga et al. 
1996; Schiemann et al. 1997; Gu et al. 1998).  
IL-6 signaling is tightly regulated by different mechanisms: (i) Degradation of 
receptor-ligand complex via internalization and ubiquitin-proteasome pathway leads 
to cessation of signaling (Thiel et al. 1998). (ii) Dephosphorylation of cytokine 
receptors or JAKs by several protein tyrosine phosphatases (Irie-Sasaki et al. 2001) 
and (iii) binding of SOCS proteins to phosphorylated tyrosines of gp130 inhibit 
cytokine signaling (Nicholson et al. 1999; Schmitz et al. 2000).  
 
1.3 The TNF-α converting enzyme TACE/ADAM17 
Several membrane proteins are cleaved at the plasma membrane to release soluble 
ectodomains which have different functions (Blobel 2005; Murphy 2008; 
Pruessmeyer and Ludwig 2009). For example, membrane bound growth factors and 
cytokines are solubilized upon shedding. One very important sheddase family is the 
“A Disintegrin And Metalloprotease” or ADAM family. ADAMs are widely expressed in 
eukaryotes with 38 family members in humans (Edwards et al. 2008). They are 
characterized by presence of a metalloprotease, a disintegrin, a cysteine-rich, an 
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EGF-like, a transmembrane and a cytoplasmic domain. TACE (TNF-α converting 
enzyme), also termed ADAM17, is a member of this family and was discovered in 
1997 as sheddase which cleaves the pro-inflammatory cytokine tumor necrosis-factor 
α (TNF-α, Black et al. 1997; Moss et al. 1997). Moreover, ADAM17 is involved in 
shedding of IL-6R, L-selectin and ligands ot the EGFR (see Fig. 1-2, Peschon et al. 













Fig. 1-2: ADAM17 mediated shedding (A) Shedding of IL-6R. (B) Shedding of EGFR ligands. 
Modified from Jones et al. 2005 and Blobel 2005. 
 
However, complete analysis of the in vivo function of ADAM17 has been hampered 
by the fact that ADAM17 knock-out (KO) mice are not viable (Peschon et al. 1998). 
Their phenotype is reminiscent to that of mice lacking TGF-α. These mice have open 
eyelids, curly vibrissae, and dense, irregular pigmentation patterns of pelage hair. 
Since TGF-α is a ligand of EGFR and is released from the cell surface by ADAM17, it 
seems that ectodomain shedding is important for EGFR signaling (Peschon et al. 
1998).  
Due to lethality of complete knock-out, conditional ADAM17 knock-out mice have 
been generated which allow the analysis of the in vivo function of ADAM17.  
For example, ADAM17flox/flox/Mx1-Cre mice allow the excision of a floxed exon by 
intraperitoneal injection of Polyinosinic-Polycytidylic Acid (pIpC). pIpC-induced 
recombination occurs in various organs with different efficiency with almost complete 
recombination in bone marrow, liver and spleen. ADAM17flox/flox/Mx1-Cre mice were 
tested in the murine model for endotoxin shock which can be induced by LPS and is 
dependent on soluble TNF-α. These mice showed a strong protection from 
endotoxin-induced lethality with lower levels of TNF-α in serum compared to wildtype 
(wt) mice. To further narrow the cell type in which ADAM17 is required for endotoxin 
shock, ADAM17flox/flox/LysM-Cre mice were generated to inactivate ADAM17 only in 
Introduction 5 
myeloid cells since these cells are critical for LPS-induced shock. 
ADAM17flox/flox/LysM-Cre mice were subjected to LPS and showed a protection to 
endotoxin shock. These findings verified that ADAM17 is a principle enzyme 
responsible for shedding of TNF-α from myeloid cells during endotoxin shock 
(Horiuchi et al. 2007). 
Furthermore, conditional ADAM17-deficient mice in which a Cre recombinase is 
under the control of the Sox-9 promoter were generated. Sox-9 is an essential 
transcription factor for skeletal development and is expressed in chondrogenic cells 
as well as in pancreas, heart, lung, brain and skin, but not in hematopoietic cells. 
ADAM17flox/flox/Sox-9-Cre mice have defects in bone metabolism, hematopoiesis, skin 
development, growth and fertility (Horiuchi et al. 2009). This study showed that 
ADAM17 is involved in bone metabolism and hematopoiesis. 
In another approach, mice with ADAM17 deficiency in all leukocytes have been used 
(Long et al. 2010). Analysis of shedding in these mice revealed that release of TNF-
alpha, TNFRI and TNFRII as well as L-selectin is impaired. Moreover, these 
ADAM17-deficient mice were protected from E.coli induced peritonitis by having 
reduced systemic pro-inflammatory cytokine levels and bacterial burden as 
compared to wildtype mice (Long et al. 2010). 
In addition, conditional ADAM17 knock-out mice were also generated in endothelial 
cells or smooth muscle cells. Therefore, floxed ADAM17 was removed by Tie2-Cre in 
endothelial cells or by smooth muscle (sm) Cre in smooth muscle cells and pericytes. 
These conditional ADAM17 knock-out mice showed no developmental defects. 
However, pathological neovascularization and growth of heterotopically injected 
tumor cells was reduced in ADAM17flox/flox/Tie2-Cre, but not in ADAM17flox/flox/sm-Cre 
mice. Furthermore, a lack of ADAM17 in endothelial cells decreased ex vivo chord 
formation which was restored by addition of the ADAM17 substrate HB-EGF 
(heparin-binding epidermal growth factor-like growth factor). These results show that 
ADAM17 is involved in pathological neovascularization in vivo (Weskamp et al. 
2010). 
All of the conditional ADAM17 knock-out mice described above provide insights into 
the in vivo function of ADAM17, however the analyses were restricted to a single 
tissue. In contrast, a mouse strain carrying a natural deletion of ADAM17 was 
discovered recently. This strain, called wave with open eyelid (woe) mouse, has 
various defects as for example wavy fur, open eyelids at birth as well as an enlarged 
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heart and oesophagus. It was shown that the ADAM17 gene is mutated leading to an 
aberrant ADAM17 splicing, diminished ADAM17 protein expression and, thereby, to a 
reduced shedding of ADAM17 substrates. Therefore, this strain provides an 
opportunity for studying the role of ADAM17 throughout postnatal development and 
homeostasis (Hassemer et al. 2010). 
In our group hypomorphic ADAM17 knock-out mice in all tissues were generated 
using a novel strategy named exon induced translational stop (EXITS). This strategy 
was based upon the usage of a new exon between exon11 and 12 of the murine 
ADAM17 gene. The targeting vector contained exon11 of ADAM17 flanked by two 
loxP sites. Within the exon11 a cryptic donor and acceptor splice site was inserted 
which generate an additional, artificial exon11a. Alternative use of the artificial 
exon11a leads to premature disruption of ADAM17 protein translation due to the in-
frame stop codon in exon11a (see Fig. 1-3) and reduction of ADAM17 protein to five 
to ten percent of wildtype level.  
E10 E11 E12wt
E10 E11 E12ex E11aNeo
STOP
 
Fig.1-3: Strategy for generation of conditional ADA M17 knock-out mice. Mice were generated 
using exon induced translational stop codon (EXITS). A new exon (E11a) was inserted between exon 
11 and 12 which started with an in-frame translational stop-codon. About 95% of the ADAM17 mRNA 
contained the new exon. Closed triangle: loxP sites, open triangle: FLP recombinase sites. Neo: 
neomycin resistance cassette. 
 
The hypomorphic ADAM17ex/ex mice are viable and show eye, heart and skin defects 
as well as compromised shedding of different ADAM17 substrates (Chalaris et al. 
accepted).  Although ADAM17 is known to be involved in inflammation and cancer, 
there is still less comprehensive understanding of its exact function and, therefore, 
hypomorphic ADAM17ex/ex mice represent an informative model to study the in vivo 
function of ADAM17 in all tissues. 
 
1.4 Inflammatory bowel disease  
Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, 
are characterized by chronic inflammation of the intestinal tissue and by subsequent 
progressive destruction of mucosal integrity (Auernhammer et al. 2005). IBD mainly 
develops between the second to fourth decade of life (Cho and Weaver 2007). 
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Patients typically suffer from frequent and chronically relapsing flares resulting in 
diarrhea, abdominal pain, rectal bleeding and malnutrition (Cho and Weaver 2007). 
Crohn’s disease occurs commonly in the ileum, but can also affect the whole gut, 
whereas ulcerative colitis always involves the rectum (Podolsky 2002). The 
pathogenesis of IBD is complex. Genetic, immunological and environmental factors 
are involved (Cho and Weaver 2007). Genome-wide screens led to the identification 
of genes that contribute to disease susceptibility. Alterations in genes of the immune 
system such as NOD2, IL-23R and ATG16L1 are specific to patients with Crohn’s 
disease, but are not observed in those with ulcerative colitis (Hugot et al. 2001; 
Ogura et al. 2001; Hampe et al. 2002). NOD2 polymorphisms were the first definitive 
risk factors identified for Crohn’s disease (Hugot et al. 2001). NOD2 is a pattern 
recognition receptor and functions as an intracellular sensor for bacterial 
peptidoglycan. The polymorphisms of NOD2 led to a dysregulated host response to 
luminal bacteria. Accordingly, the discovery of the association of NOD2 
polymorphism with susceptibility to Crohn’s disease supported the hypothesis that 
Crohn’s disease results from a genetically dysregulated host response to luminal 
bacteria (Cho and Weaver 2007). Furthermore, a nonsynonymous single nucleotide 
polymorphism (SNP) in ATG16L1 gene was discovered which is also associated with 
the increased risk for Crohn’s disease (Hampe et al. 2007). Mutations affecting 
autophagy factors, which are involved in restricting microbial growth within the host 
tissue (Amano et al. 2006), resulted in reduced pathogen clearance and more 
intracellular growth of bacterial pathogens (Xavier and Podolsky 2007). SNPs were 
also found in genes responsible for ulcerative colitis including STAT3 or XBP1 
(Franke et al. 2008; Kaser et al. 2008).  
Furthermore, many inflammatory mediators, such as chemokines and cytokines, are 
dysregulated. Patients suffering from Crohn’s disease displayed increased IL-6 levels 
in the serum (Mitsuyama et al. 1991) as well as elevated sIL-6R levels (Mitsuyama et 
al. 1995). Soluble IL-6R is released by neutrophils and macrophages through 
shedding of IL-6R from the cell surface. This mechanism is induced by either 
apoptosis (Rose-John and Heinrich 1994), acute phase protein CRP in macrophages 
(Jones et al. 1999), by bacterial toxin (Walev et al. 1996) or by microbial 
metalloproteinases in human monocytes (Vollmer et al. 1996). Thereby, IL-6 can bind 
to sIL-6R to form the IL-6/sIL-6R complex. As T cells which are also activated during 
Crohn’s disease (Rose-John et al. 2009) express membrane bound gp130, the IL-
6/sIL-6R complex can bind to gp130 to activate the expression and nuclear 
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translocation of STAT3. Thus, anti-apoptotic genes are expressed which leads to an 
increased resistance to apoptosis and a perpetuation of intestinal inflammation (see 
Fig. 1-4).  
Latest studies have underlined the importance of STAT3 in intestinal inflammation. 
Mice deficient in STAT3 develop only mild colitis (Alonzi et al. 2004), whereas 
disease was more severe in mice with a hyperactivated form of STAT3 (Jenkins et al. 
2005). Furthermore, Samp1/YIT mice which develop spontaneous intestinal 
inflammation showed a strong expression of phosphorylated STAT3 during course of 
colitis (Mitsuyama et al. 2006). This indicates a crucial role of STAT3 in the 













Fig. 1-4: Schematic model of IL-6 trans-signaling i n inflammatory bowel diesease.  Modified from 
Atraya and Neurath, 2005 and Rose-John et al., 2009. 
 
In several other published studies the functional role of IL-6 and STAT3 in 
inflammation associated colon cancer was analyzed (Bollrath et al. 2009; 
Grivennikov et al. 2009; Matsumoto et al. 2010).  
Grivennikov et al. reported that IL-6 knockout mice develop less tumors, but display a 
higher inflammatory score than wildtype animals. IL-6 knock-out mice had increased 
apoptosis and less cellular proliferation. The group of Bollrath et al. showed that a 
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genetic hyperactivation of STAT3 leads to an increased tumor incidence together 
with a resistance to colitis. Both groups could verify that the severity of inflammation 
was dramatically increased in mice with a deletion of STAT3 in intestinal epithelial 
cells. Furthermore, STAT3 activation is increased during colitis associated 
premalignant cancer (CApC) or chronic colitis (CC) in Balb/c mice (Matsumoto et al. 
2010). 
From these studies two different functions for IL-6 are obvious. On the one hand, IL-6 
in complex with sIL-6R is responsible for the apoptotic resistance of T cells which 
leads to the progression of the disease. On the other hand, IL-6 together with 
membrane bound IL-6R plays a role in the regenerative response of intestinal 
epithelial cells to cellular damage.  
Since IL-6 trans-signaling seems to be involved in progression of IBD, it was 
elucidated if the disease can be ameliorated by blocking IL-6 trans-signaling alone. In 
a TNBS-induced colitis model, IL-6 as well as IL-6/sIL-6R complex was blocked by 
using anti-IL-6R antibody, whereas injection of recombinant sgp130Fc interfered with 
IL-6 trans-signaling. It was shown that inflammation was decreased compared to 
control mice (Atreya et al. 2000). Mice treated with antil-IL6R antibody showed less 
weight loss than untreated mice and normal colon architecture. Furthermore, the 
colitis score indicated that mice treated with sgp130Fc or anti-IL-6R antibody 
displayed less inflammation than control mice. Interestingly, treatment of patients 
with Crohn’s disease using anti-IL-6R antibody successfully prevented and treated 
inflammation (Ito 2005).  
 
1.5 Mouse models of intestinal inflammation 
Animal models of intestinal inflammation are indispensable for the understanding of 
inflammatory bowel disease. The most widely used chemically induced models of 
intestinal inflammation are trinitro benzene sulfonic acid (TNBS), oxazolone or 
dextran sodium sulfate (DSS) colitis (Wirtz et al. 2007). TNBS as well as oxazolone 
are haptenating substances in ethanol and are given intrarectal to different 
susceptible strains. Ethanol breaks the mucosal barrier integrity, whereas TNBS and 
oxazolone induce a T cell mediated response against hapten-modified autologous 
proteins or luminal antigens. Contrary, DSS is applied in drinking water of mice and 
induces an acute colitis characterized by bloody diarrhea, ulcerations and infiltrations 
with granulocytes (Okayasu et al. 1990). DSS is directly toxic to gut epithelial cells of 
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the basal crypts and, therefore, affects the integrity of the mucosal barrier (Wirtz et al. 
2007). As T and B cell deficient mice also develop severe intestinal inflammation 
after DSS administration, the adaptive immune system is not involved in this model 
(Dieleman et al. 1994). Hence, the DSS-induced colitis model is useful to study the 
contribution of innate immune mechanisms to colitis.  
 
1.6 Aim of the work 
The metalloprotease ADAM17 is responsible for limited proteolysis of more than 40 
substrates (Pruessmeyer and Ludwig 2009) and known to be involved in different 
inflammatory disorders. Since conditional ADAM17 knock-out mice only show the 
consequence of its ablation in a single tissue, transgenic mice with dramatically 
reduced ADAM17 levels in all cells were generated in our group (Chalaris et al. 
accepted). These mice completely lost the ability to shed L-selectin, TNF- RII and 
TNF-α from the cell surface. Are these transgenic mice protected from excessive 
inflammatory responses and, therefore, from IBD? 
To elucidate this issue the inflammatory response in ADAM17ex/ex mice was analyzed 
using a DSS-colitis model. 
Furthermore, other signaling pathways such as IL-6 trans-signaling are involved in 
inflammatory disorders e.g. IBD. Blocking this pathway with sgp130Fc as well as 
anti-IL-6R antibody showed reduced levels of inflammation in a TNBS-induced colitis 
model (Atreya et al. 2000). Surprisingly, IL-6 knock-out mice were highly inflamed 
after DSS-induced colitis (Grivennikov et al. 2009). Hence, it was interesting to 
analyze if C57BL/6N mice treated with sgp130Fc and anti-IL-6 antibody are protected 
from IBD in a DSS-induced colitis model.  
Therefore, specific goals of this thesis were: 
(i)  to establish DSS-colitis model; 
(ii) to monitor the specific intensity of inflammatory response to colitis in ADAM17 ex/ex 
mice as well as mice injected with sgp130Fc and anti-IL-6 antibody using several 
physiological parameters including weight loss, rectal bleeding, colonoscopy, tissue 
integrity as well as permeability, cellular proliferation, monitoring of cytokine as well 





2.1 ADAM17 ex/ex mice are highly susceptible to DSS-induced colitis  
The metalloprotease ADAM17 is responsible for shedding of TNF-α, L-selectin as 
well as EGFR ligands. Hypomorphic ADAM17ex/ex mice were generated using the 
new EXITS strategy (see 1.3). The usage of the new exon E11a which contains a 
premature stop codon between exon 11 and exon 12 of the murine ADAM17 gene 
was tested in brain and liver tissue by RT-PCR (see Fig. 2-1 A, B).  In wildtype mice 
a single band of 380bp was detected, whereas heterozygous ADAM17wt/ex mice 
showed an additional band of 550bp due to insertion of the new exon. In 
homozygous ADAM17ex/ex mice only the 550bp band could be detected. Interestingly, 

























Fig. 2-1: Generation of hypomorphic ADAM17 ex/ex mice. (A) RT-PCR analysis was performed with 
primers for exon10 (E10) and exon12 (E12) of the ADAM17 gene. (B) mRNA from brain and liver 
tissue was isolated and analyzed by RT-PCR. The 380bp wildtype fragment was detected in wildtype 
and heterozygous brain and liver samples, whereas the 550bp transcript containing the new exon 
(E11a) was only detectable in heterozygous and homozygous tissue samples. (C) ADAM17 Western 
blot of membrane fractions of mouse embryonic fibroblasts (MEFs). ADAM17 expression was 
detectable in wt and ADAM17wt/ex MEFs, but was absent in ADAM17ex/ex MEFs. HEK cells were used 
as positive control. 
 
Furthermore, expression of ADAM17 in cell lysates of mouse embryonic fibroblasts 
(MEFs) was analyzed. No ADAM17 protein was detectable in MEFs from 
ADAM17ex/ex mice, whereas MEFs from wildtype and heterozygous ADAM17 mice 
expressed both the pro- as well as the mature form of ADAM17 (see Fig. 2-1 C). 
Results 12 
ADAM17 protein expression was also undetectable in other tissues, whereas mRNA 
expression of ADAM17 was unchanged (data not shown). These results indicate that 
viable mice with undetectable levels of ADAM17 protein in all tissues were generated 
successfully.  
Homozygous ADAM17ex/ex mice developed eye, heart and skin defects which 
represents the TGF-α knock-out mice phenotype. Furthermore, the release of known 
substrates of ADAM17 (Black et al. 1997; Moss et al. 1997) was analyzed. Therefore, 
splenic B cells were isolated from ADAM17ex/ex, ADAM17wt/ex as well as wildtype mice 
and stimulated with the phorbol ester PMA which induces shedding of ADAM17 
substrates (Arribas et al. 1996; Matthews et al. 2003). Wildtype and heterozygous 
ADAM17wt/ex mice showed a dramatic loss of L-selectin from the cell surface, 
whereas homozygous mice had the same L-selectin expression level before and 

































































Fig. 2-2: Functional characterization of ADAM17 ex/ex mice. (A) Isolated splenic B cells from wt 
(n=2), ADAM17wt/ex (n=3) and ADAM17ex/ex (n=4) mice were stimulated with PMA (100nM). Cells were 
double stained with anti-L-selectin and anti-B220 mAbs and analyzed by flow cytometry. Shedding of 
L-selectin was impaired in B cells derived from ADAM17ex/ex mice. (B and C) Isolated splenocytes from 
wildtype (n=2), ADAM17wt/ex (n=3) and ADAM17ex/ex (n=6) were stimulated with LPS. Supernatant was 
collected and TNF-α as well as TNFRII levels were determined by ELISA. Shedding of TNF-α and 
TNFRII was impaired in splenocytes from ADAM17
ex/ex mice. 
 
Furthermore, shedding of TNF-α as well as TNF-RII was analyzed in splenocytes 
isolated from wildtype, heterozygous ADAM17wt/ex or homozygous ADAM17ex/ex mice 
after stimulation with lipopolysaccharide (LPS). LPS can also induce shedding of 
different ADAM17 substrates (Mullberg et al. 1995). As shown on Fig. 2-2 B, 
splenocytes from wt and heterozygous ADAM17wt/ex mice generated similar amounts 
of soluble TNF-α after LPS stimulation, whereas homozygous ADAM17ex/ex mice 
produced no soluble TNF-α. Same results were obtained for soluble TNFRII (see Fig. 
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2-2 C). Taken together, shedding of L-selectin, TNF-α and TNFRII is impaired in 
ADAM17ex/ex mice. 
TNF-α is a pro-inflammatory cytokine and implicated in many diseases such as 
Crohn’s disease or rheumatoid arthritis (Black et al. 1997, Moss et al. 1997). 
Moreover, EGFR ligands are known to be involved in STAT3 dependent cell 
proliferation (Sanderson et al. 2006). As these proteins are substrates of ADAM17, it 
was interesting to analyze if ADAM17ex/ex mice are resistant or more susceptible to 
DSS-induced colitis. 
ADAM17ex/ex mice as well as heterozygous ADAM17 and wildtype mice were treated 
with 2% DSS in the drinking water for five days followed by five days of water. 
Disease severity was monitored daily by weight progression, hemoccult test and 
stool consistency. A group of six wildtype, seven heterozygous and eight 
homozygous animals were used. Interestingly, five of eight homozygous ADAM17ex/ex 
mice died during the DSS treatment and the residual animals lost about 20% of their 
weight (Fig. 2-3). In contrast to that, wildtype and heterozygous mice lost only little 
weight (5%) and all animals survived. Treated ADAM17ex/ex mice died mostly 
immediately after the DSS cycle showing that ADAM17ex/ex mice are highly 
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Fig. 2-3: Weight progression during DSS-induced col itis. 2% DSS was applied in drinking water 
for 5d followed by 5d of water. wt/wt: wildtype ADAM17wt/wt mice, wt/ex: heterozygous ADAM17wt/ex 
mice, ex/ex: homozygous ADAM17ex/ex mice. The numbers in brackets indicate the number of mice 
used for the experiment and asterisks show the number of remaining mice. 
 
Disease severity was further assessed by colonoscopy. Under normal conditions, 
luminescence in the colon is maintained meaning other organs are still visible 
through the colon and mice are not vulnerable to contact bleeding. After DSS 
treatment the colons of wildtype and heterozygous mice showed normal architecture 
represented by maintained luminescence, absence of diarrhea and no bloody stool, 
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low hyperemia and no increased contact vulnerability. On the contrary, homozygous 
ADAM17ex/ex mice are highly inflamed as indicated by diarrhea, absence of 
luminescence, increased contact vulnerability, bloody stool and hyperemia (see Fig. 
2-4 A). Thus, endoscopic score for ADAM17ex/ex mice is high, indicating strong 
inflammation (Fig. 2-4 B). Untreated animals were also examined to control colon 
architecture of wildtype, heterozygous and ADAM17ex/ex mice. Untreated mice 
showed no signs of inflammation as depicted in colonoscopy as well as in the 





























Fig. 2-4: Colonoscopy of untreated and treated wt, ADAM17wt/ex  and ADAM17 ex/ex mice. (A) 
Untreated mice are shown in the upper panel, treated mice in the lower panel. (B) Endoscopic score 
(MEICS) after DSS-treatment. 
 
The Disease Activity Index (DAI) comprises of the combined score of rectal bleeding, 
weight loss and histology at day ten (see Fig. 2-5 A). As shown on Fig. 2-5 B, the DAI 




























Fig. 2-5: DAI score after DSS-treatment. (A) Composition of DAI. (B) Index with values are shown as 
means ± SD. 
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Colon sections were immunostained with anti-ADAM17 antibody to localize ADAM17 
protein in DSS-induced colitis. As shown on Fig. 2-6, ADAM17 protein was 




Fig. 2-6: ADAM17 protein expression in crypts of th e colon of wt and ADAM17 ex/ex mice. Colon 
sections were immunostained with anti-ADAM17 mAb labeled with peroxidase. Figure from Chalaris et 
al. accepted. Bars represent 200µm. 
 
HE staining of the colon of mice treated with DSS revealed minor signs of 
inflammation in wt and heterozygous mice but strong signs in homozygous ADAM17 
mice. In all three genotypes the epithelium was destroyed by DSS toxicity to gut 
epithelial cells. A clear difference was detected in the architecture of the crypts. In 
mildly inflamed mice like wt and heterozygous ADAM17 animals the crypts are 
almost intact. In highly inflamed ADAM17ex/ex mice the crypt structure was completely 
lost after day five and day ten (see Fig. 2-7). There are two possible causes why 
crypts are destroyed: (i) Apoptosis could be promoted or (ii) regenerative proliferation 
of epithelial cells might be impaired.  
Interestingly, previous data point to the latter possibility as a similar damage was 
seen in mice with a targeted disruption of STAT3 in intestinal epithelial cells treated 
with AOM/DSS as reported recently (Bollrath et al. 2009; Grivennikov et al. 2009). 
This showed that STAT3 is important for survival and proliferation of intestinal 
epithelial cells (Bollrath et al. 2009).  
To analyze the regenerative response of the gut epithelium during DSS-induced 
colitis, cell proliferation was measured via BrdU staining. Cells were labeled by 
intraperitoneal injection of BrdU two hours before sacrifice. As shown on Fig. 2-7, 
proliferating cells could only be detected in crypts of the gut of wildtype and 
heterozygous ADAM17 animals but not in ADAM17ex/ex mice. As mice lacking STAT3 
fail to induce cell proliferation, the activation status of STAT3 in DSS treated mice 
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was examined. STAT3 is phosphorylated in wildtype and heterozygous mice, 











Fig. 2-7: Immunohistochemistry of the colon.  HE (upper panels), BrdU (middle panels), pSTAT3 
and cyclinD1 (lower panels) staining of colons from wt, ADAM17wt/ex and ADAM17ex/ex mice challenged 
for 5d and 10d with DSS. Scale bars denote 100µm. 
 
The proliferative response was further analyzed by cyclinD1 expression in colon 
sections. CyclinD1 is a cell cycle regulator and activated in its early phase. 
ADAM17ex/ex mice showed no cyclinD1 expression in contrast to wildtype and 
heterozygous animals (Fig. 2-7). Taken together, these results indicate that the 
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regenerative response in ADAM17ex/ex mice is impaired due to inability to activate 
tyrosine kinase receptor (e.g. EGFR) mediated STAT signaling. 
A coordinated regenerative response is required to maintain the intestinal barrier 
function. An impaired barrier integrity leads to fast and severe progression of the 
disease. Therefore, membrane integrity was measured by permeability for FITC-
dextran (Yoshikawa et al. 1984). FITC-Dextran was administered by gavage four 
hours before sacrifice. Blood samples were collected and serum was analyzed for 
presence of FITC-Dextran. Indeed, upon DSS challenge, the intestinal barrier 
became permeable for FITC-Dextran in ADAM17ex/ex mice. FITC-Dextran levels in 
serum of ADAM17ex/ex mice were highly increased compared to wildtype and 
heterozygous mice (see Fig. 2-8 A). In unchallenged mice, no difference in 
permeability could be detected. Furthermore, MPO (marker for activated neutrophils, 
Breckwoldt et al. 2008) activity was measured in wildtype and ADAM17wt/ex mice (see 
Fig. 2-8 B). MPO is secreted by activated neutrophils and macrophages during 
inflammation and after phagocytosis of bacteria. A strong increase in MPO was 
detected in ADAM17ex/ex mice, whereas wildtype mice showed no MPO activity. 
Thus, these results indicate that the inflammation level was higher in homozygous 

























Fig. 2-8: Permeability and MPO levels in the colon of wt and ADAM17 ex/ex mice. DSS colitis was 
induced as described. (A) Plasma FITC-dextran concentrations in wt (n=7) and ADAM17ex/ex (n=7) 
mice 4h after FITC-dextran administration. (B) MPO levels in the colon of ADAM17ex/ex mice (n=5) 
were increased compared to wt mice (n=4). Values are shown as means ± SD. Figure taken from 
Chalaris et al. accepted.  
 
Moreover, secretion of different cytokines in colon organ cultures from DSS-treated 
animals was analyzed by ELISA. KC (keratinocyte chemoattractant protein) and 
MCP-1 (monocyte chemoattractant protein-1) are marker for activated neutrophils as 
well as macrophages and are released during inflammation (Luedde et al. 2002). The 
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levels of the inflammatory chemokines MCP-1 and KC were higher in ADAM17ex/ex 
mice compared to wt and ADAM17wt/ex mice (see Fig. 2-9 A, B). Furthermore, levels 
of the anti-inflammatory cytokine IL-10 and of the IL-6 related cytokine IL-11 were 
determined. Levels of both cytokines were increased in ADAM17ex/ex mice compared 
to wt and heterozygous mice (see Fig. 2-9 C, D). 
Interestingly, levels of these chemo- and cytokines were also increased in DSS-




























































Fig. 2-9: Chemokine as well as anti-inflammatory cy tokine levels in colon organ cultures. (A - D) 
Supernatants of colon organ cultures were assayed by ELISA for levels of the chemokines KC (A; day 
10; wt/wt: n=10; wt/ex: n=5; ex/ex: n=6), MCP-1 (B; day 10; wt/wt: n=10; wt/ex: n=5; ex/ex: n=6) and of 
the cytokines IL-10 (C; day 10; wt/wt: n=10; wt/ex: n=5; ex/ex: n=6) and IL-11 (D; day 10; wt/wt: n=10; 
wt/ex: n=5; ex/ex: n=6). Values are shown as means ± SD. 
 
Furthermore, the levels of the pro-inflammatory cytokine IFN-γ as well as of the 
























































Fig. 2-10: Pro-inflammatory cytokine levels in colo n organ cultures. (A - D) Supernatants of colon 
organ cultures were assayed by ELISA for levels of the cytokines IL-21 (A), IL-12 (B), IL-17 (C) and 
IFN-γ (D). Analysis was perfomed at day 10 with wt/wt: n=10; wt/ex: n=5; ex/ex: n=6. Values are 
shown as means ± SD. 
 
Due to the strong inflammatory response, infiltration of different immune cells was 
measured. Anti-CD68 is a marker for infiltrating macrophages, whereas infiltrating T-
lymphocytes can be detected by anti-CD3 antibody. As shown on Fig. 2-11 A, an 
increase of CD68 positive cells in intestinal tissue sections was detected in DSS-
treated ADAM17ex/ex mice, whereas unchallenged mice exhibited no difference in 
CD68 positive cells. Nearly the same picture was seen in sections which were 
screened for CD3 positive cells. In the intestine of unchallenged mice the number of 
CD3 positive T cells was slightly different compared to negative control. ADAM17ex/ex 
mice treated with DSS, however, displayed a massive influx of CD3 positive T cells 























Fig. 2-11: Macrophages/Monocytes and CD3 positive T  cells in intestinal tissue sections of 
DSS-treated ADAM17 wt/wt  or ADAM17 ex/ex mice. (A) Colonic tissue sections of wt ADAM17 and 
ADAM17ex/ex mice stained with anti-CD68 antibody to obtain influx levels of macrophages/monocytes. 
(B) Colonic tissue sections of wt and ADAM17ex/ex mice stained with anti-CD3 antibody to visualize 
CD3 positive T cells. 
 
All data suggest that activity of STAT3 which is involved in cell proliferation is 
impaired in ADAM17ex/ex mice and, therefore, leads to failure of intestinal epithelial 
cells to proliferate, but the role of apoptosis is still unknown. Since ADAM17ex/ex mice 
could not cleave and activate ligands of EGFR and EGFR signaling is known to be 
involved in STAT3 dependent cell proliferation  (Sanderson et al. 2006), the influence 





2.2 Treatment of ADAM17 ex/ex mice with EGFR ligands:  
Amelioration of disease? 
The metalloprotease ADAM17 is involved in shedding of IL-6R, TNF-α, L-selectin and 
ligands of the EGFR (Peschon et al. 1998; Horiuchi et al. 2005; Sahin and Blobel 
2007). It is known that activation of EGFR signaling induces cell proliferation and 
regeneration due to STAT3 phosphorylation (Sanderson et al. 2006). Hypomorphic 
ADAM17ex/ex mice lost the ability to shed TNF-α, L-selectin and ligands of the EGFR 
from the cell surface (see section 2.1). The downstream signaling pathway of EGFR 
ligands or TNF-α in ADAM17ex/ex mice is intact but not activated. Furthermore, it was 
shown that ADAM17ex/ex mice were highly susceptible to DSS-induced colitis due to a 
breakdown of the intestinal epithelial barrier (see section 2.1). Can one rescue the 
disease progression by treatment with EGFR ligands? Are the mice then protected 
from DSS-induced colitis? 
To elucidate this issue, wt and ADAM17ex/ex mice were injected with TGF-α and EGF 
during DSS-induced colitis. Wt and ADAM17ex/ex mice daily injected with EGFR 
ligands lost less weight than PBS injected mice after treatment with DSS (see Fig. 2-
12 A). Histological colon sections of ADAM17ex/ex mice treated with either EGF or 
TGF showed normal architecture including destroyed epithelium but less crypt loss 
compared to DSS-treated ADAM17ex/ex mice. Furthermore, proliferation of cells of the 
crypts was analyzed. Interestingly, crypt cell proliferation of EGF or TGF-α treated 
ADAM17ex/ex mice could be restored compared to DSS-treated ADAM17ex/ex mice 
(see Fig. 2-12 B). Hence, phosphorylation of STAT3 in homozygous ADAM17ex/ex 
mice could be detected after DSS-induced colitis and TGF-α treatment compared to 
DSS-treated ADAM17ex/ex mice. This demonstrated that activation of EGFR signaling 
pathway can rescue proliferation of intestinal epithelial cells to induce a regenerative 
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Fig. 2-12: Injection of EGFR ligands leads to ameli oration of DSS-induced colitis in ADAM17 ex/ex  
mice. (A) Weight progression during DSS-induced colitis of wt and ADAM17ex/ex mice treated with 
recombinant EGF. (B) Proliferation of crypt cells and phosphorylation of STAT3 in wt and ex/ex mice 
before and after injection of recombinant TGF-α. Bars represent 100µm. Figure taken from Chalaris et 
al. accepted. 
 
2.3 Influence of sgp130Fc and anti-IL-6 antibody on  DSS-induced 
colitis 
Several signaling pathways are known to be involved in inflammatory bowel disease. 
As shown in section 2.1, ADAM17 mediated EGFR signaling is one signaling 
pathway which contributes to initiation and progression of DSS-induced colitis. This 
pathway induces phosphorylation of STAT3 and leads to regeneration of intestinal 
epithelial cells during DSS-induced colitis. Furthermore, ADAM17 is known to be 
involved in shedding of IL-6R from the cell surface. Soluble IL-6R binds to IL-6 and 
initiates IL-6 trans-signaling which is also implicated in Crohn’s disease and 
ulcerative colitis. This pathway can be blocked using sgp130Fc or anti-IL-6R 
antibody. To elucidate the influence of sgp130Fc as well as anti-IL-6R antibody in 
IBD as potential therapeutic agents, Balb/c mice were injected with either sgp130Fc 
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or anti-IL-6R antibody in a TNBS-induced colitis model (Atreya et al. 2000). 
Interestingly, sgp130Fc as well as anti-IL-6R antibody treated mice showed less 
inflammation than control mice indicating that colitis can be ameliorated by interfering 
with IL-6 trans-signaling. The TNBS-induced colitis model is considered to reflect the 
pathogenesis of Crohn’s disease (Maxwell and Viney 2009). To verify the role of IL-6 
trans-signaling in ulcerative colitis, the DSS-induced colitis model was used. 
C57BL/6N mice were injected with 250µg sgp130Fc or 250µg anti-IL-6 antibody at 
day zero as well as day five and were treated with 2% DSS for five days followed by 
five days of water. Each group was comprised of six animals and weight loss was 
recorded daily.  
As depicted in Fig. 2-13, all mice lost approximately 10% body weight during the 
experiment with a slight tendency for less weight loss in sgp130Fc treated mice than 


























Fig. 2-13: Weight progression of mice during DSS-in duced colitis treated with sg130Fc and 
anti-IL-6 mAb. Every group was comprised of six animals. 
 
Furthermore, inflammation status of sgp130Fc or anti-IL-6 antibody treated mice was 
determined by colonoscopy (see Fig. 2-14 A). Mice treated with anti-IL-6 antibody 
were highly inflamed, had diarrhea, showed less luminescence and a strong increase 
in contact vulnerability. Control mice were also inflamed, e.g. having diarrhea and 
decreased luminescence, but less signs of inflammation were visible compared to 
anti-IL-6 antibody treated mice (see Fig. 2-14 A).  
In contrast to that, sgp130Fc treated mice showed almost no signs of inflammation. 
The stool consistency as well as blood flow was normal and luminescence 
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maintained. Furthermore, disease activity index comprised of weight loss and HE 
staining was determined and showed that sgp130Fc treated mice were less inflamed 
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Fig. 2-14: Colonoscopy and disease activity index ( DAI) of mice injected with sgp130Fc and 
anti-IL-6 mAb. (A) sgp130Fc treated mice showed less inflammation signs, whereas anti-IL-6 mAb 
treated and control mice were inflamed. (B) DAI comprised of weight loss and HE staining is increased 
in anti-IL-6 antibody treated mice compared to control or sgp130Fc treated mice.  
 
Analysis of colon architecture by HE staining after DSS treatment showed that three 
out of six anti-IL-6 antibody treated mice were highly inflamed as seen by complete 
loss of intact crypts. The remaining three anti-IL-6 antibody treated mice had a 
destroyed epithelium caused by DSS, but the crypts were almost intact. The colon 
architecture of sgp130Fc treated mice showed a disrupted epithelium, but the crypts 
were completely intact concluding that these mice have less inflammation caused by 
DSS. Control mice displayed nearly the same inflammation level as sgp130Fc 

















Fig. 2-15: HE staining of colon sections after anti -IL-6 mAb or sgp130Fc treatment and DSS-
induced colitis. Epithelium is disrupted in all colon sections due to DSS application. sgp130Fc 
treated and control mice still have intact crypts, whereas anti-IL-6 mAb treatment led to a complete 
crypt destruction. One control mice died at day ten during colonoscopy. Bars represent 200µm. 
 
These results are visualized by the inflammation score calculated from HE stained 
colon sections of each mouse. As shown on Tab. 2-1, sgp130Fc treated as well as 
control mice displayed an inflammation score of 1.2, whereas the level of anti-IL-6 
antibody treated mice was significantly higher being 2.0. 
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Tab.2-1: Inflammation score of DSS-treated mice.  Control mouse #6 died during colonoscopy and, 
therefore, no score could be calculated for this individual.1= epithelium destroyed, crypts intact; 2= 
epithelium disrupted, partial crypt lost; 3= epithelium destroyed, complete crypt lost. 
 
# control sgp130Fc α-IL6 mab 
1 1 1 3 
2 1 2 2 
3 2 1 1 
4 1 1 1 
5 1 1 2 
6 n.a. 1 3 
Ø 1.2 1.2 2.0 
 
Chemo- and cytokine secretion in colon organ culture was analyzed by ELISA. 
Levels of the chemoattractant proteins KC and MCP-1 are increased during an 
inflammation. As shown on Fig. 2-18, levels of KC as well as of MCP-1 showed an 
increased tendency in all mice after DSS-induced colitis indicating that all mice were 
inflamed. However, levels of KC as well as MCP-1 were higher in anti-IL-6 antibody 
treated mice than in sgp130Fc treated or control mice but failed to be significant (Fig. 
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Fig. 2-16: Cytokine and chemokine secretion in colo n organ cultures of treated mice. (A - D) 
Supernatants of colon organ cultures were harvested and analyzed by ELISA for KC (A; sgp130Fc 
n=6; anti-IL-6 ab n=6; control n=5), MCP-1 (B; sgp130Fc n=6; anti-IL-6 ab n=6; control n=5), IL-11 (C; 
sgp130Fc n=6; anti-IL-6 ab n=6; control n=5) and IL-10 (D; sgp130Fc n=6; anti-IL-6 ab n=6; control 
n=5).  
 
The anti-inflammatory cytokines IL-10 as well as IL-11 are involved in prohibition of 
excessive inflammation reactions and IL-11 is considered to block the production of 
IL-6 (Walmsley et al. 1998; Murray 2005). In the latter experiment, protein levels of 
IL-10 and IL-11 were tendentially increased in sgp130Fc as well as in anti-IL-6 
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antibody treated mice showing that inflammation was tried to combat (see Fig. 2-16 
C, D). 
Furthermore, MPO levels in colons of treated and untreated mice were measured 
showing no significant differences among the three different treatments (see Fig. 2-
17). MPO levels increased as a result of IBD which indicates the presence of 
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Fig. 2-17: MPO activity after DSS treatment in colo n of mice injected with sgp130Fc, anti-IL-6 
mAb or control mice. 
 
Taken together, sgp130Fc has positively influenced disease progression indicating 
that this protein might ameliorate DSS-induced colitis. However, mice treated with 
anti-IL-6 antibody during DSS-induced colitis were more inflamed than sgp130Fc 
treated and control mice. 
 
2.4 Which protease is responsible for the release o f CD27 from the 
cell surface? 
CD27 is a 55kDa type I transmembrane receptor protein belonging to the tumor 
necrosis factor (TNF) receptor family and is expressed by peripheral T cells, mature 
thymocytes, memory B cells and NK cells (Bigler et al. 1988). CD70, the ligand of 
CD27, is only transiently present on cells of the immune system upon activation 
(Borst et al. 2005). After interaction of CD27 with CD70, a truncated form of CD27 is 
released, most probably by a membrane-linked protease (Loenen et al. 1992). This 
interaction is important for an effective T cell response in vivo. However, continuous 
CD27-CD70 interactions may cause immune dysregulation and immunopathology in 
conditions of chronic immune activation (Nolte et al. 2009). Inhibiting the CD27-CD70 
signaling pathway by blockade of CD70 or absence of CD27 suppresses TNBS-
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induced colitis (Manocha et al. 2009). Furthermore, it was shown that CD27 is shed 
from the T cell surface upon stimulation with benzoyl ATP (BzATP) which is acting 
via P2Y purinergic receptors (Boyer and Harden 1989). Shedding of CD27 is 
dependent on the receptor P2X7 (Moon et al. 2006), but the responsible protease 
remains unknown. 
Members of the ADAM family, especially ADAM17, are involved in shedding of tumor 
necrosis factor receptors (TNFRs). CD27 is a member of the TNFR family and 
cleaved from the cell surface by an unidentified protease. In the absence of CD27, 
TNBS-induced colitis is suppressed, whereas mice with decreased levels of 
ADAM17, which might shed CD27 from the cell surface, exhibit severe colitis (see 
section 2.1). The working hypothesis was that ADAM17 may be the main sheddase 
for CD27 in vivo. Therefore, ADAM17 mediated shedding of CD27 might down-
regulate CD27 signaling and, thereby, dampen disease signs in DSS-induced colitis. 
To test this hypothesis, spleen cells of C57BL/6N mice were isolated and treated with 
300µM BzATP to induce the release of different proteins from the cell surface. To 
analyze if ADAM10 or ADAM17 are involved in shedding of CD27, cells were 
additionally incubated with inhibitors of ADAM10 (GI, Ludwig et al. 2005) or both 
ADAM17 and ADAM10 (GW, Ludwig et al. 2005). Cells were analyzed by FACS for 
CD27 surface expression. As shown on Fig. 2-18, percentage of CD27-positive 
lymphocytes drastically decreases by treatment with BzATP. The decrease of CD27 
from the cell surface of lymphocytes due to BzATP stimulation could be blocked to 
the same degree by GI (ADAM10) or GW (ADAM10/17). This indicated that ADAM10 
rather than ADAM17 is involved in shedding of CD27. 
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Fig. 2-18: FACS analysis of stimulated spleen cells  from C57BL/6N mice. Spleen cells were 
isolated from C57BL/6N mice and stimulated with 300µM BzATP or BzATP and 3µM inhibitors GI or 
GW. Four mice were used for mean and SD. A10: ADAM10; A17: ADAM17. 
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To validate our in vivo finding data in another model, Ba/F3-gp130-IL-6R as well as 
MEF cells were analyzed for presence of CD27 on cell surface using FACS. As 
shown on Fig. 2-19, both cell lines, Ba/F3-gp130-IL-6R and MEFs, do not express 
CD27. Since COS7 as well as HEK cells also do not produce CD27 (Garcia et al. 
2004, Akiba et al. 1998), any of the four cell lines can only be used for further 






















































Fig.  2-19: Analysis of CD27 expression in Ba/F3-gp 130-IL6R as well as MEF cells. (A) 106 Ba/F3-
gp130-IL-6R cells were stained with PE hamster anti-mouse CD27. Cells gated in P1 (left panel) 
displaying Ba/F3-gp130-IL6R cells were analyzed in right panel for CD27 expression. (B) 106 MEF 
cells were stained with PE hamster anti-mouse CD27. In the left panel, P1 shows the gate for MEF 
cells in which the CD27 expression was determined (right panel). (A) as well as (B) shows that both 
cell lines are negative for CD27 expression. 
 
For the construction of the CD27 expression plasmid, CD27 open reading frame (orf) 
was amplified from murine spleen cell cDNA and cloned into pcDNA3.1 containing a 
Flag- as well as His6-tag. Afterwards, a cDNA encoding an alkaline phosphatase (AP) 
was inserted into the CD27 construct for detecting CD27 in e.g. Western blot or AP-

















Fig. 2-20: Scheme of cloning CD27 into pcDNA3.1. CD27 orf was amplified from murine spleen cell 
cDNA and inserted into pcDNA3.1 containing signal peptide (SP), Flag- as well as His6-tag. 
Furthermore, cDNA for human alkaline phosphatase was ligated into pcDNA3.1 between Flag-tag and 
SP. 
 
COS7 as well as HEK cells were successfully transfected transiently with the 
expression construct encoding CD27 as revealed by Western blotting (see Fig. 2-21). 
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Fig. 2-21: Western blot analysis of transiently tra nsfected COS7 and HEK cells. COS7 cells as 
well as HEK cells were transiently transfected with pcDNA3.1-CD27, pcDNA3.1-CD27-AP or pEGFP. 
Lysate and supernatant was collected and analyzed for expression of CD27. Interestingly, in 
supernatant of HEK cells transfected with CD27-AP, CD27 was detected 48 hours after transfection 
using FLAG antibody indicating that the protein is released from cell surface without stimulus. ut: 
untransfected. 
 
Interestingly, 48 hours after transfection CD27 could be detected in the supernatant 
of HEK cells indicating that shedding occurred without any inductor. Furthermore, the 
release of CD27 was analyzed via AP activity. If CD27 is released into the 
supernatant (SN), AP activity is increased in SN and decreased in the lysate which 
can be measured at 405nm after coloration. As shown on Fig. 2-22, AP activity in the 
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supernatant of CD27-AP expressing HEK cells is increased compared to control cells 
without using a stimulus 48 hours after transfection.  
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Fig. 2-22: Shedding analysis with alkaline phosphat ase activity. HEK cells were transiently 
transfected with CD27-AP or CD27 construct. 48h after transfection, lysate and supernatant was 
collected and AP activity was measured at 405nm. Shedding occurred in HEK cells without stimulating 
the cells. ut: untransfected cells. 
 
To verify if ADAM10 is involved in shedding of CD27, HEK cells were pretreated with 
the ADAM10 inhibitor GI for 30 minutes. Besides BzATP, other substances can also 
induce shedding. Therefore, cells were treated with ionomycin. Ionomycin leads to 
calcium influx into cells, induces apoptosis and shedding of different membrane 
proteins. AP activity was measured and the ratio of supernatant to lysate was 
calculated. As shown on Fig. 2-23, after addition of ionomycin, CD27 is released in 





















Fig. 2-23: Shedding analysis of transfected HEK cel ls with ionomycin and ADAM10 inhibitor GI. 
HEK cells were transiently transfected with CD27-AP construct. 48 hours after transfection, cells were 
stimulated with ionomycin to induce shedding or with ionomycin and GI to inhibit shedding. Ratio of 
supernatant (SN) and lysate (L) was calculated. Shedding of CD27 was diminished in presence of 
ADAM10 inhibitor GI. 
 
These initial experiments showed that ADAM10 rather than ADAM17 might be 
involved in shedding of CD27 from the cell surface. However, these findings will be 
verified by using (i) MEFs deficient for ADAM10 or (ii) mice with T cell specific 











3.1 Role of ADAM17 in DSS-induced colitis 
ADAM17 is known to be involved in shedding of different proteins from cell surface 
e.g. IL-6R, L-selectin and ligands of EGFR (Peschon et al. 1998; Horiuchi et al. 2005; 
Sahin and Blobel 2007). It is expressed by immune cells but also in most other 
tissues and is upregulated during inflammation and cancer (Becker et al. 2005; 
Kenny 2007). ADAM17 deficient mice are not viable (Peschon et al. 1998). 
Conditional ADAM17 knock-out mice are available, but characterization of ADAM17 
is restricted mostly to one tissue or cell type. Therefore, hypomorphic ADAM17ex/ex 
mice were generated (see section 1.3). These mice are viable, but display eye, heart 
and skin defects. Furthermore, shedding of different substrates, such as L-selectin, 
TNF-α and EGFR ligands, in these mice is impaired.  
Since the molecular mechanism of inflammatory bowel disease still remains 
unknown, it was very interesting to test if a knock-out of ADAM17 has consequences 
on the development of inflammatory diseases. Colitis can be induced in mice by 
application of DSS. ADAM17ex/ex mice as well as heterozygous and wildtype mice 
were treated with 2% DSS for five days followed by five days of water. 
Under normal conditions, the colon architecture of ADAM17ex/ex mice is intact and 
cellular proliferation in the intestine was not affected by the knock-out indicating that 
ADAM17 activation is not needed for this process. However, ADAM17ex/ex mice are 
highly susceptible to DSS-induced colitis compared to heterozygous and wildtype 
mice. ADAM17ex/ex mice displayed severe weight loss during DSS treatment (see Fig. 
2-3). DSS is directly toxic to gut epithelial cells and, therefore, affects the barrier 
integrity against microbial invaders. This barrier is influenced by residential 
commensal bacteria, rapid epithelial turnover, innate immune responses and 
epithelial barrier integrity. DSS-treated ADAM17ex/ex mice failed to maintain the 
barrier function as shown by colonoscopy (Fig. 2-4), HE staining (Fig. 2-7) and FITC-
Dextran permeability (Fig. 2-8). HE staining also revealed that in ADAM17ex/ex mice 
the crypts are completely lost compared to wildtype and heterozygous ADAM17 
mice. Thus, there are two possible causes why the crypts are destroyed: (i) apoptosis 
is promoted or (ii) regenerative proliferation might be impaired. Therefore, colon 
sections were analyzed for phosphorylation of STAT3 as well as cyclinD1 
expression. Phosphorylation of STAT3 (Fig. 2-7) as well as expression of cyclinD1 
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(Fig. 2-7) - both are marker of proliferating cells - are impaired in DSS-treated 
ADAM17ex/ex mice. Normally, phosphorylated STAT3 induces proliferation of 
intestinal epithelial cells and, therefore, activates the regeneration of a destroyed 
epithelium. These results indicate that the regenerative response in ADAM17ex/ex 
mice is affected due to absence of the protease ADAM17. These two functions – 
maintaining barrier integrity and regeneration of intestinal epithelial cells – seem to 
be dominant towards the reduced activity of the immune system which is a 
consequence of impaired ADAM17 mediated shedding of substrates such as TNF-α. 
However, promoted apoptosis could not be excluded because after ten days of DSS 
treatment no crypts could be detected in colon sections. To verify that apoptosis is 
not involved in crypt loss, TUNEL as well well Acridin orange staining on colon 
tissues has to be performed. Moreover, to analyze the timing when the regenerative 
response is established, phosphorylation of STAT3 as well as CyclinD1 expression 
has to be analyzed at earlier time points when crypts are not completely absent 
during DSS-induced colitis.   
Furthermore, ADAM17 is the main sheddase for TNF-α (Black et al. 1997) and also 
for several ligands of EGFR (Sunnarborg et al. 2002). Thus, it was suggested that 
blocking ADAM17 might be used as therapeutic strategy during different 
inflammatory diseases (Moss and Bartsch 2004) and cancer (Kenny 2007). Anti-
TNF-α mAbs such as infliximab were generated and used successfully for treatment 
against rheumatoid arthritis (Elliott et al. 1993). Since antibody production is 
expensive, other therapeutic agents which are less costly and have a better safety 
profile might prove to be useful (Moss et al. 2008). However, inhibitors of 
metalloproteases as therapeutic drugs often failed as they caused many side effects  
(Moss and Bartsch 2004). Nevertheless, inhibitors of ADAM17 are available and 
currently in clinical trials (Moss et al. 2008). As shown in this work, deletion of 
ADAM17 caused a lack of stress-induced tissue regeneration and underlines that this 
acts dominantly over the anti-inflammatory property of this protease. Targeting 
ADAM17 during DSS-induced colitis, therefore, could not ameliorate disease 
progression but might be a helpful target in other diseases e.g. cancer. ADAM17 is 
known to be involved in breast cancer progression (McGowan et al. 2007; Zheng et 
al. 2009) and contributes to cancer progression through activation of EGFR-PI3K-
AKT signaling pathway (Zheng et al. 2009). Involvement in cancer progression, 
therefore, provides further impetus for exploiting ADAM17 as a new target for cancer 
treatment. 
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Interestingly, mice lacking TGF-α also develop a severe colitis induced by DSS 
compared to wildtype mice (Egger et al. 1997). However, mice overexpressing TGF-
α showed reduced susceptibility to DSS-induced colitis suggesting that TGF-α is a 
pivotal mediator of protection and/or healing mechanisms in the colon (Egger et al. 
1998). Thus, ligands of the EGFR such as TGF-α and EGF were used as a potential 
therapeutic drug during DSS-induced colitis of ADAM17ex/ex mice. Interestingly, TGF-
α treated ADAM17ex/ex mice exhibited less inflammation compared to untreated mice 
during colitis. Moreover, proliferation of intestinal epithelial cells could be restored in 
the presence of EGF or TGF-α (see Fig. 2-12).  
Taken together, analysis of inflammatory bowel disease in the DSS-induced colitis 
model in hypomorphic ADAM17 mice showed that the metalloprotease exhibits a 
dual role: (i) ADAM17 sheds TNF-α from the cell surface to activate the immune 
system. In this case, ADAM17 has pro-inflammatory properties. (ii) Furthermore, 
ADAM17 is involved in shedding of EGFR ligands to activate a coordinated 
regenerative response, being anti-apoptotic (see Fig. 3-1). Interestingly, studying 
hypomorphic ADAM17ex/ex mice revealed both detrimal and beneficial properties of 
the metalloprotease ADAM17, whereas ADAM17 was shown to exhibit only 
desruptive functions in other conditional ADAM17 knock-out mouse models.  
In this respect, the ADAM17ex/ex mouse model is well suited to analyze the in vivo 
functions and consequences after therapeutic blockade of ADAM17, in which 90-95% 









Fig. 3-1: Dual role of ADAM17 in inflammatory disea ses. ADAM17 is involved in shedding of EGFR 
ligands as well as TNF-α and can act pro- as well as anti-inflammatory. Shedding of EGFR ligands 
leads to regeneration of e.g. intestinal epithelial cells, whereas shedding of TNF-α is involved in 





3.2  Role of sgp130Fc and anti-IL-6 antibody in DSS -induced colitis 
The mechanisms of initiation and progression of inflammatory bowel disease are not 
yet clarified, but it is known that different signaling pathways e.g. EGFR signaling 
(see above) or IL-6 trans-signaling (Atreya et al. 2000) are involved. Activation of the 
IL-6 trans-signaling pathway plays an important role during Crohn’s disease (Rose-
John and Heinrich 1994; Peters et al. 1998; Mullberg et al. 2000). This pathway can 
be blocked by sgp130Fc which is an inhibitor of IL-6 trans-signaling (Jostock et al. 
2001).  
Inflammatory bowel disease can be induced in mice by different chemical agents e.g. 
TNBS, oxazolone or DSS. TNBS as well as oxazolone induce a T cell mediated 
immune response, whereas DSS influences the barrier integrity and, therefore, is 
important to analyze the role of the innate immune system.  
In a TNBS-induced colitis model, the IL-6 trans-signaling inhibitors sgp130Fc and 
anti-IL-6R antibody could ameliorate disease progression and positively influenced 
colitis (Atreya et al. 2000). Furthermore, anti-IL-6R antibody is used for treatment of 
patients with Castleman’s disease, rheumatoid arthritis as well as juvenile idiopathic 
arthritis (Kishimoto 2010).  
But which influence do sgp130Fc as well as anti-IL-6 antibody exert during DSS-
induced colitis? To elucidate this issue, C57BL/6N mice were treated with sgp130Fc 
or anti-IL-6 antibody during DSS-induced colitis. To monitor the inflammation status, 
weight loss was recorded daily. sgp130Fc and anti-IL-6 antibody treated mice lost 
weight during the DSS cycle, but displayed no significant difference from control 
animals (see Fig. 2-13). Interestingly, colonoscopy and HE staining revealed that 
sgp130Fc treated mice had less inflammation than anti-IL-6 antibody treated and 
control mice (see Fig. 2-14, 2-15). These results indicate that sgp130Fc can 
ameliorate disease progression also in DSS-induced colitis, whereas anti-IL-6 
antibody treated mice were inflamed and not protected from colitis. As mentioned 
above, inhibiting IL-6 trans-signaling via anti-IL-6R antibody was able to ameliorate 
TNBS-induced colitis (Atreya et al. 2000), whereas using anti-IL-6 antibody does not 
protect from DSS-induced colitis. How can this apparent contradiction be explained? 
Interestingly, IL-6 knock-out mice exhibit severe colitis after DSS-treatment 
(Grivennikov et al. 2009), although IL-6 trans-signaling and classic signaling is 
blocked. IL-6 increases proliferation of intestinal epithelial cells as well as their 
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resistance to apoptosis and might effect tissue regeneration. In the absence of IL-6, 
proliferation as well as regeneration was impaired and led to disease progression. 
This phenotype was also seen in C57BL/6N mice treated with anti-IL-6 antibody 
during DSS-induced colitis. On the other hand, a permanent increase of IL-6 could 
lead to proliferation of intestinal epithelial cells and, therefore, disease progression is 
amplified. If this part of IL-6 is influenced for example by blocking the IL-6 signaling 
pathway with anti-IL-6R antibody or sgp130Fc, the disease could be ameliorated. 
Furthermore, different colitis models were used to analyze the role of IL-6 trans-
signaling. TNBS-induced colitis leads to T cell mediated immune responses and most 
symptoms correspond to Crohn’s disease – one major inflammatory bowel disease 
(Wirtz et al. 2007). In contrast to this, DSS-induced colitis affects the barrier integrity 
and the innate immune system plays a major role in this model (Wirtz et al. 2007). 
Concerning on inflammatory bowel disease, it is postulated that DSS-induced colitis 
mimics ulcerative colitis. Therefore, blocking IL-6 trans-signaling with either anti-IL-
6R antibody or anti-IL6 antibody could have different functions in Crohn’s disease as 
well as ulcerative colitis. Thus, different inflammatory responses were analyzed 
although they are belonging to inflammatory bowel disease. To verify their roles each 
antibody has to be tested in both colitis models. Furthermore, anti-IL-6R antibody 
was used in clinical trials against Castleman’s disease and different kinds of arthritis 
but not for Crohn’s disease or ulcerative colitis until now (Kishimoto 2010).  
Taken together, IL-6 exerts two different functions in inflammatory bowel disease and 
other chronic disorders. The function of the protein is balancing between anti- and 
pro-inflammatory properties. Up to now it is unclear how the balance is regulated. 
Related to inflammatory bowel disease, mice might be protected or highly susceptible 
to DSS-induced colitis depending on which protein is chosen for inhibition of IL-6 
trans-signaling. sgp130Fc might have protective effects on colitis and, therefore, 
represents a potential but powerful therapeutic agent of IBD, whereas anti-IL-6 
antibody might aggravate the disease progression and, thus, does not seem to 
represent a useful drug.  
  
3.3 CD27, a protein involved in IBD seems to be she d by ADAM10 
CD27 is a type I transmembrane receptor protein belonging to the tumor necrosis 
factor (TNF) receptor family and is expressed by peripheral T cells, mature 
thymocytes, memory B cells and NK cells (Nolte et al. 2009). CD70, the ligand of 
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CD27, is only present on activated T cells (Borst et al. 2005). Interaction of CD27 
with CD70 is important for an effective T cell response in vivo. Interestingly, CD27-
CD70 signaling pathway was shown to be involved in inflammatory bowel disease 
(Manocha et al. 2009) and blocking this pathway may provide a potential tool for 
therapeutic intervention in IBD. T cells from CD27 knock-out mice were transferred 
into Rag-/- mice and wildtype T cells transferred recipient mice were treated with anti-
CD70 antibody. TNBS was administered and clinical symptoms of colitis were 
monitored. Interestingly, blockade of CD27-CD70 pathway attenuated TNBS-induced 
colitis (Manocha et al. 2009). Furthermore, membrane bound CD27 can be 
inactivated by shedding from the cell surface. This mechanism could be induced by 
BzATP, but the involved protease remains unknown (Moon et al. 2006). 
As shown in section 2.1, mice with a deletion of ADAM17 are highly susceptible to 
DSS-induced colitis. Therefore, it was hypothesized that ADAM17 might be involved 
in the release of CD27 from the cell surface to inhibit the CD27-CD70 pathway and, 











Fig. 3-2: Hypothetical model of involvement of ADAM 17 in CD27 shedding. Activation of CD27-
CD70 pathway leads to severe colitis, whereas blocking this pathway by inhibiting CD27 exhibits a 
mild form of colitis. CD27 can be inactivated by shedding, but the responsible protease is unknown 
suggesting that ADAM17 might be involved. 
 
To elucidate this issue, shedding experiments were carried out using isolated spleen 
cells of C57BL/6N mice. Shedding was induced by administration of BzATP alone or 
in the presence of an inhibitor of ADAM10 (GI, Ludwig et al. 2005) or both ADAM10 
and ADAM17 (GW, Ludwig et al. 2005). This in vitro analysis suggests that CD27 
might be shed by ADAM10 and not ADAM17. To verify these results using 
recombinant technology, shedding experiments were carried out in COS7 as well as 
HEK cells transiently transfected with constructs coding for CD27 fused to alkaline 
phosphatase. Interestingly, shedding of CD27 occurred without any stimulus 48 
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hours after transfection. Furthermore, cells were treated with the ADAM10 inhibitor 
GI. Shedding of CD27 could be blocked by GI (see Fig. 2-23) pointing out that 
ADAM10 is involved in release of CD27 as already shown in spleen cells. 
To clearify the release of CD27 from the cell surface in vivo, ADAM10KO mice could 
prove useful. Unfortunately, ADAM10KO mice are not viable (Hartmann et al. 2002). 
Therefore, it is difficult to analyze CD27 shedding in vivo. To overcome this problem, 
mouse embryonic fibroblasts deleted in ADAM10 or conditional ADAM10KO mice 
could be used to underline the in vitro experiments.  
Conditional ADAM10KO mice are being generated at the moment using a CD4+-Cre 
promoter (Jürgen Scheller, Institute of Biochemistry, Kiel, personal communication). 
By expressing Cre recombinase under the control of the CD4+ promoter in mice, 
deletion of floxed ADAM10 segments will be induced in CD4-positive T cells. 
However, these mice first have to be characterized, e.g. if ADAM10 is indeed down-
regulated or even absent in T-lymphocytes. Then these mice can be used for 
shedding analyses in vivo. 
Furthermore, it would be interesting to analyze conditional ADAM10KO mice during 
TNBS- or DSS-induced colitis. If ADAM10 indeed is involved in CD27 shedding, mice 
with a deletion of this protease might be more susceptible to TNBS-induced colitis 
because the CD27-CD70 pathway is not inactivated and induces progression of the 
disease. 
All initial experiments point to ADAM10 as the main sheddase for CD27 and showed 
that inflammatory bowel disease is regulated by a complex interplay of different 
molecules.  
 
3.4 Current understanding of the molecular framewor k of IBD 
Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal 
tract that occurs in immunocompetent individuals (Manocha et al. 2009). Despite 
intensive study of IBD pathogenesis, the mechanisms which contribute to disease 
initiation and progression still largely remain unknown. Inflammatory bowel disease 
can be induced in a mouse model for example by administration of DSS in drinking 
water (Wirtz et al. 2007). 
The results obtained in this work have shown that many factors are involved in the 
pathogenesis of DSS-induced colitis. First, the function of the metalloprotease 
Discussion 40 
ADAM17 during DSS-induced colitis was analyzed (see section 2.1). Interestingly, 
mice with a deletion of ADAM17 exhibit severe colitis. It is postulated that ADAM17 
activates EGFR signaling pathway by shedding of EGFR ligands leading to 
suppression of DSS-induced colitis. Furthermore, the role of IL-6 classic as well as 
trans-signaling in inflammatory bowel disease was determined (see section 2.3). IL-6 
classic and trans-signaling exhibit a dual role during inflammatory bowel disease: (i) 
Inhibiting IL-6 trans-signaling pathway specifically by sgp130Fc might ameliorate 
disease progression. (ii) Blocking both pathways by anti-IL-6 mAb indicates high 
susceptibility to IBD. Another signaling pathway which is known to promote disease 
progression is CD27-CD70 (see Fig. 3-3). Inhibiting this pathway by ADAM10 might 
have a protective role for the initiation of DSS-induced colitis. 
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Fig. 3-3: Model of contributing pathways in inflamm atory bowel disease induced by DSS. IL-6 
trans-signaling promotes inflammatory bowel disease and can be inhibited by sgp130Fc. However, 
combined IL-6 signaling – comprised of classic and trans-signaling – as well as EGFR and CD27-
CD70 signaling attenuate disease progression. 
Discussion 41 
 
Interestingly, the major molecule, which IL-6 signaling as well as EGFR signaling 
share, is STAT3. STAT3 has two different functions: (i) it can act anti-apoptotic, e.g. 
during cancer or (ii) cell-proliferative during regeneration depending on the pathway. 
During IBD, STAT3 might be the decisive step. CD27/CD70 pathway signals via 
MAPK or NF-κB and also promotes cell survival and cell proliferation (Garcia et al. 
2004; Neron et al. 2006).  
Taken together, the data of this work demonstrate that inflammatory bowel disease is 
controlled by a complex molecular framework of at least four signal transduction 
pathways (see Fig. 3-3). These include IL-6 classic- and trans-signaling, ADAM17 
mediated EGFR-signaling as well as suggested ADAM10 controlled CD27-CD70 
signaling. Moreover, this network is even more complex, as these pathways are also 
interconnected. However, further experiments are required for a full understanding of 
























Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, 
are chronic inflammatory disorders of the gut charaterized by bloody diarrhea, 
ulcerations and infiltrations of inflammatory cells. The molecular mechanisms of the 
disease still remain unknown. In a mouse model, IBD can be induced i.a. by 
administration of DSS in drinking water for several days.  
The metalloprotease ADAM17 is responsible for shedding of different substrates 
such as TNF-α, L-selectin or ligands of EGFR. Since ADAM17 knock-out mice are 
not viable, hypomorphic ADAM17ex/ex mice have been generated by our group. 
Shedding of L-selectin, EGFR ligands and TNF-α is impaired in these mice. To 
elucidate the role of ADAM17 in IBD, mice were treated with DSS. Surprisingly, 
ADAM17ex/ex mice were highly susceptible to DSS-induced colitis. They suffered from 
severe weight loss, destruction of crypts and increased permeability of the intestinal 
epithelium. Moreover, proliferation of intestinal epithelial cells in ADAM17ex/ex mice is 
impaired and treatment of ADAM17ex/ex mice with TGF or EGF could restore a 
regenerative response.  
Other signaling pathways such as IL-6 classic- and trans-signaling are also involved 
in IBD. It is known that blocking the IL-6 trans-signaling pathway with sgp130Fc or 
anti-IL-6R antibody could ameliorate disease progression during TNBS-induced 
colitis. To elucidate the role of IL-6 trans-signaling during DSS-induced colitis, 
C57BL/6N mice were injected with sgp130Fc and anti-IL-6 antibody. Although no 
significant difference in weight loss could be detected, colon architecture, determined 
by colonoscopy as well as HE staining, revealed that sgp130Fc injected mice have 
less inflammation than control mice or those treated with anti-IL-6 antibody. This 
indicates that sgp130Fc might ameliorate disease progression and, therefore, 
represents a potential therapeutic agent of IBD.  
Taken together, all results demonstrate that different signaling pathways, e.g. EGFR 
signaling, IL-6 classic and trans-signaling as well as CD27-CD70 signaling are 







Entzündliche Darmerkrankungen, zu denen Morbus Crohn und Colitis Ulcerosa 
gehören, sind chronisch-entzündliche Darmerkrankungen, welche durch blutigen 
Durchfall, Ulzerationen und Einwanderungen von Immunzellen gekennzeichnet sind. 
Die molekularen Mechanismen sind jedoch bislang ungeklärt. Colitis kann im 
Mausmodell u.a. durch Applikation von DSS im Trinkwasser induziert werden. 
Die Metalloprotease ADAM17 ist verantwortlich für die Freisetzung verschiedener 
Substrate wie TNF-α, L-Selectin, oder Liganden des EGFR. Da ADAM17 Knock-out 
Mäuse nicht lebensfähig sind, wurden hypomorphe ADAM17ex/ex Mäuse generiert. 
Die Freisetzung von L-Selectin, TNF-α sowie EGFR Liganden ist in diesen Mäusen 
beeinträchtigt. Um die Rolle von ADAM17 in entzündlichen Darmerkrankungen zu 
untersuchen, wurden ADAM17ex/ex Mäuse mit DSS behandelt. Überraschenderweise 
waren diese Mäuse stark anfällig für DSS-induzierte Colitis. Die Mäuse litten unter 
starkem Gewichtsverlust, Zerstörung der Krypten sowie einer erhöhten Permeabilität 
des Darmepithels. Proliferation der intestinalen epithelialen Zellen scheint in diesen 
Mäusen beeinträchtigt zu sein und eine Behandlung mit TGF-α oder EGF konnte die 
Regeneration dieser Zellen wiederherstellen.  
Andere Signalwege wie z.B. der klassische IL-6 Signalweg oder IL-6 trans-signaling 
sind ebenfalls in chronisch-entzündlichen Darmerkrankungen involviert. Es ist 
bekannt, dass eine TNBS-induzierte Colitis durch Blockierung des Signalweges mit 
sgp130Fc oder anti-IL-6R Antikörper verbessert werden kann. Um die Rolle des IL-6 
trans-signaling während einer DSS-induzierten Colitis zu untersuchen, wurden 
C57BL/6N Mäuse mit sgp130Fc und anti-IL-6 Antikörper behandelt. Die Mäuse 
zeigten keinen Gewichtsunterschied, jedoch verdeutlichte die Darmarchitektur, 
welche koloskopisch sowie an HE Schnitten untersucht wurde, dass sgp130Fc 
behandelte Mäuse weniger Entzündung aufwiesen als mit anti-IL-6 Antikörper 
behandelte. Dies deutete an, dass sgp130Fc den Verlauf der Erkrankung verbessern 
und somit ein potentielles Therapeutikum für entzündliche Darmerkrankungen 
darstellen könnte.  
Zusammenfassend zeigen die Ergebnisse, dass verschiedene Signalwege wie 
EGFR Signaling, klassischer IL-6 Signalweg, IL-6 trans-signaling sowie der CD27-





6.1 Organisms and cell lines 
Escherichia Coli XL1 Blue    Stratagene 
sgp130Fc tg mice (C57BL/6N background)   Rabe et al. 2008 
ADAM17ex/ex mice  Chalaris et al. accepted 
IL-6 knockout mice Charles River Laboratories 
C57BL6/N mice              Charles River Laboratories 
COS7 (monkey kidney fibroblast cell line ) DSMZ, German Resource Centre for 
Biological Material 




Acetic acid       Roth 
Agar-Agar      Roth 
Agarose, SeaKem LE Agarose Cambrex BioScience Rocklan  
Ammonium persulfate (APS)   Merck 
Ampicillin      Roth 
Azoxymethane      Sigma-Aldrich 
BM Blue POD Substrat     Roche 
Bovine serum albumin (BSA, Fraction V) ICN Biomedicals Inc. 
Bromphenol blue     Sigma 
dNTPs       Fermentas 
Dimethyl sulfoxide (DMSO)    Roth 
Dextran sulfate sodium (DSS, MW 40,000 Da) TdB Cosultancy 
EDTA        Gibco     
Ethanol       Roth 
Ethidium bromide     Roth 
Fetal calf serum (FCS)     PAA 
Formaldehyde     Roth 
FITC-Dextran 4000     Sigma-Aldrich 
G-418-sulfate     PAA 
GeneRuler DNA Ladder     Fermentas 
Material 45 
Glycine       Roth 
Glycerol      Roth 
HCl        Roth 
Isopropanol       Roth 
2-Mercaptoethanol      Merck 
Methanol       Roth 
MgCl2       Fermentas 
Milk powder       Roth 
Myeloperoxidase (MPO)    Sigma-Aldrich 
Penicillin/Streptomycine (P/S)    PAA  
p-Nitrophenol-Phosphate    Sigma-Aldrich 
Polyacrylamide Rotiphorese Gel 30  Roth 
Sodium chloride      Roth 
Sodium dodecyl sulfate (SDS)    Roth 
Sodium hydroxide      Roth 
Sulfuric acid       Sigma-Aldrich   
N,N,N’,N’-tetramethylethan-1,2-diamin  Roth 
Tryptone/peptone      Roth 
Tween 20       Roth 
Yeast extract      Roth 
 
6.3 Media 
DMEM culture medium PAA, supplemented with 10% (v/v) FCS, 
1% (v/v) P/S  
RPMI-1640 culture medium PAA, supplemented with 10% (v/v) FCS, 1% 
(v/v) P/S, 1% (v/v) HEPES, 1mM ß-
mercaptoethanol, without L-glutamine  
LB medium 10g NaCl, 10g tryptone, 5g yeast extract, ad 
1l Milli-Q H2O, autoclaved  
LB agar medium  20g Agar-Agar in 1l LB medium, autoclaved  
LBamp Agar 20g Agar-Agar in 1l LB medium, autoclaved, 




6.4 Buffers and solutions 
6.4.1 Different solutions and buffers 
Ampicillin stock solution 50mg/ml  
Ammonium persulfate (APS) 10% (w/v) in Milli-Q H2O 
BM blue POD Roche 
6x DNA loading dye Fermentas 
Erythrocytes lysis buffer 150mM NH4Cl, 10mM KHCO3, 100nM EDTA 
FACS buffer 1% BSA, 2mM EDTA, in 1xPBS 
MPO buffer 0.05 KPO4, 0.5% C19H42BrN  
5x TBE 44.5mM Tris, 44.5mM boric acid, 10mM 
EDTA, pH 8.0 
Trypsin/EDTA (10x) PAA 
SDS stock solution 10% (w/v) in Milli-Q H2O 
AP buffer 0.1M Glycine, 1mM MgCl2, 1mM ZnCl2, pH 
10.8 
Lysis buffer 50mM Tris, pH 7.5, 150mM NaCl, 1% (v/v) 
Triton X-100, one Complete pellet 
 
6.4.2 SDS-polyacrylamide gelelectrophoresis and Wes tern blot 
10x SDS running buffer  92M glycine, 0.25M Tris-HCl, pH 8.3, 1M 
SDS  
4x SDS loading dye 500mM Tris-HCl pH 6.8, 50% (v/v) glycerol, 
10% (w/v) SDS, 2% (v/v) β-mercaptoethanol, 
1% (w/v) bromphenolblue 
Transfer buffer 25mM Tris, 0.2M glycine, 20% methanol, pH 
8.5 
10x TBS (Tris buffered Saline) 50mM Tris, 1.5M NaCl, pH 7.5 
TBST 1x TBS, 0.1% Tween 20 
Blocking solution 3% (w/v) BSA or milk powder in TBST 
 
6.4.3 ELISA 
Washing buffer 0.05% Tween 20 in 1x PBS 
Reagent diluent 1% BSA, 0.05% Tween 20 in 1x PBS 
Stop Solution  1.8M H2SO4 
10x PBS (phosphate buffer saline) 0.1M NaH2PO4, 1.5M NaCl, pH 7.5 
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6.4.4 Immunohistochemistry 
Shadon Gill III Hematoxylin  Thermo Scientific 
Giemsa’s azure eosin methylene blue  Merck 
AEC substrate  Dako 
Blocking reagent  Dako 
Antibody Diluent Dako 
DAPI (20mg/ml) Sigma-Aldrich 
 
6.4.5 Cell stimulation 
BzATP    Sigma-Aldrich 
GI254023X   Ludwig et al. 2005 
GW280264X   Ludwig et al. 2005 
Fc-Block    BD Biosciences Pharmingen 
Rat serum    Jackson ImmunoResearch 
Ionomycin calcium salt Sigma-Aldrich 
 
6.5 Enzymes 




Goat Anti-Mouse IgG POD Pierce  
Goat Anti-Rabbit IgG POD Pierce  
Rabbit Anti-mouse IgG Dako 
Cy3-conjugated donkey Anti-mouse IgG Jackson Immuno Research 
FITC labeled donkey Anti-mouse IgG Jackson Immuno Research 
Goat Anti-CD27 (C-20) IgG Santa Cruz Biotechnology, Inc. 
Mouse Anti-BrdU IgG Sigma-Aldrich 
PE hamster Anti-mouse CD27 BD Biosciences Pharmingen 
APC hamster Anti-mouse CD3e BD Biosciences Pharmingen 
FITC rat Anti-mouse B220 BD Biosciences Pharmingen 
FITC mouse Anti-rat CD4  BD Biosciences Pharmingen 
PE rat Anti-mouse CD62L  BD Biosciences Pharmingen 
Rabbit Anti-CD3 IgG abcam 
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Mouse Anti-CD68 IgG Santa Cruz Biotechnology 
Rabbit Anti-Phospho Stat3 IgG Cell Signaling 
Rabbit Anti-CyclinD1 IgG Cell Signaling 
Rat Anti-mouse MP5-20F3 In Vivo BioTech   
Rabbit Anti-FLAG Sigma-Aldrich 
Rabbit Anti-ADAM17  Chemicon 
 
6.7 Oligonucleotides (Primer) 
All oligonucleotides used were synthesized from Metabion. Sequences are shown in 
Tab. 6-1. 
Tab. 6-1: Used primers and their sequences 
Name Sequence (5’-3’) Tm (°C) 
   
3’floxADAM17geno CTTATTATTCTCGTGGTCACC 54.2 
5’floxADAM17geno TATGTGATAGGTGTAATG 46.9 
T7-Promotor TAATACGACTCACTATAGGG 52 
M13-reverse CATGGTCATAGCTGTTTCC 54.5 
IL-6KO-Screen- P1 TTCCATCCAGTTGCCTTCTTGG 60.6 
IL-6KO-Screen- P2 TTCTCATTTCCACATTTCCCAG 55.8 










ECL Plus Westernblotting   
Detection System  Amersham  
NucleoSpin ExtractII Macherey-Nagel 
NucleobondAX  Macherey-Nagel 
NucleoSpin RNAII Macherey-Nagel 
DuoSet Mouse KC (DY453) R&D Systems 
DuoSet Mouse JE (DY479) R&D Systems 
DuoSet Mouse IL-10 (DY417) R&D Systems 
DuoSet Mouse IL-11 (DY418) R&D Systems  
DuoSet Mouse IL-6 (DY479)  R&D Systems 
DuoSet Mouse IL-17 (DY421) R&D Systems 
DuoSet Mouse TNF-α (DY410)  R&D Systems 
DuoSet Mouse sTNFRII (DY426) R&D Systems 
DuoSet Mouse IL-12 p70 (DY419)  R&D Systems 
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DuoSet Mouse IL-21 (DY594) R&D Systems 
DuoSet Mouse IFN-γ (DY485)  R&D Systems 
DuoSet Human sgp130 (DY228)  R&D Systems 
Haemoccult Test  Beckmann Coulter 




pMOWS  Ketteler et al. 2002 
For detailed vector descriptions see appendix. 
 
6.10 Recombinant proteins 
sgp130Fc purified from supernatant of stably 
transfected CHO cells as described (Jostock 
et al. 2001) 
 
6.11 Electric devices and other materials 
6.11.1 Centrifuges 
Centrifuge 5417R Eppendorf 
Speed-Vac Universal Vacuum   
System Plus UVS400A  Savant 
 
6.11.2 Incubators 
HeraCell CO2-Incubator Heraeus Instruments 
Thermomixer compact Eppendorf 
Assistent RM5  EYDAM 
 
6.11.3 Electrophoresis devices and power supplies 
Mini-sub cell BIO-RAD 
Mini-Protein 3 Electrophoresis Cell BIO-RAD 
Trans-Blot SD Semi-Dry Transfer Cell BIO-RAD 




Microscope TELAVAL 31  ZEISS 
Fluorescence microscope CKX41  Olympus 
 
6.11.5 Other devices 
Multipipette Eppendorf 
Sterile working bench Hera safe Heraeus 
Milli-Q Academic System Millipore 
GelDoc 2000  BIO-RAD 
Robocycler Gradient 96  Stratagene 
PeqStar 96 Universal Gradient Peqlab 
FluorChemQ  Alpha Innotech 
NanoDrop ND-1000 spectrophotometer Thermo Scientific 
HOPKINS Optik 64019BA  Karl Stolz AIDA VET 
BDFACSCanto  BD Biosciences Pharmingen 
96-well-Photometer SCT Rainbow  Tecan 
 
6.11.6 Consumables 
0.5ml, 1.5ml and 2ml micro tube Sarstedt 
Petri dishes (∅ 10cm) Sarstedt 
Pipette tips Sarstedt 
Tube 15ml and 50ml Sarstedt 
Hyperfilm  Amersham Biosciences   
PVDF-membrane Highbond P  Amersham Biosciences 
Tissue culture plate (∅ 10cm)  Sarstedt  
Tissue culture dish 6/96-well   Sarstedt 
Nunc-ImmunoPlate Thermo Fisher Scientific 
100 Sterican size 1/2/14/18/20 Braun 
Injekt-F (1ml)  Braun 
Surgical Disposable Scalpels  Braun 




7.1 Isolation of RNA 
Extraction of RNA from mouse spleen cells was performed using the NucleoSpin 
RNAII Kit from Macherey-Nagel according to manufacturer’s protocol. 
 
7.2 cDNA synthesis 
cDNA synthesis was performed using RevertAidM-MuLV Reverse Transcriptase 
according to manufacturer’s protocol. 
 
7.3 Polymerase chain reaction (PCR) 
Nucleic acid sequences can be amplified by using polymerase chain reaction. This 
method can be divided into three different steps: (i) denaturation, (ii) annealing and 
(iii) elongation. After DNA denaturation specific primers bind during the annealing 
phase to the template and the defined region of the DNA is replicated during the 
elongation phase. By repeated denaturation, annealing and elongation for several 
cycles the specific DNA sequence is amplified exponentially. 
Standard PCR was performed using the components shown in Tab. 7-1. The PCR 
was carried out with the following PCR program: 95°C 5min, up to 35x (95°C 1min, 
Tm 1min, 72°C 1min), 72°C 5min. T m equals the primer annealing temperature as 
estimated by the program pDRAW32. PCR products were analyzed by agarose gel 
electrophoresis.  
 
Tab. 7-1: Components of a standard PCR 
Component Volume [µl] 
Template 1-100ng X 
DreamTaq buffer (10x) 5 
MgCl2 (25mM) 4 
dNTP-Mix (10mM) 1 
Primer A (100pM) 2.5 
Primer B (100pM) 2.5 
DreamTaq DNA Polymerase (1U/µl) 1 
Milli Q H2O ad 50 
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7.4 Reverse-transcriptase (RT) PCR 
RNA was isolated from different organs and 2 µg were reverse transcribed into cDNA 
using Reverse Aid M-MuLV reverse transcriptase (Fermentas).  ADAM17 transcripts 
were subsequently amplified by PCR using the following primer pair: 
3’ und 5’ floxADAM17geno. 
 
7.5 Agarose gel electrophoresis 
Nucleic acids were separated in 0.7% to 2% (w/v) agarose gels supplemented with 
0.05% (v/v) ethidium bromide. The electrophoresis was performed in horizontal gel 
chambers at 90 to 120 volt. Fragment sizes were estimated using DNA ladders 
(Fermentas). 
 
7.6 DNA digestion with restriction enzymes 
Restriction enzymes cut DNA at specific nucleotide sequences. The recognition 
sequences are palindromic and vary in length between 4 and 8 nucleotides. The 
digestion leads, depending on the enzyme, to sticky or blunt ends. Reactions were 
performed according to manufacturer’s protocol. 
 
7.7 Extraction of nucleic acids from agarose gels 
Bands were excised from agarose gel and purified using NucleoSpin ExtractII Kit 
(Macherey-Nagel) according to manufacturer’s protocol. 
 
7.8 Ligation  
Purified DNA-fragments were ligated into linearized plasmids using T4-DNA-ligase 
(Fermentas) with five-fold molar excess of insert. The reaction was prepared 
according to manufacturer’s protocol, incubated over night at 4°C and used directly 
for transformation (see section 7.9). 
 
7.9 Transformation of chemocompetent E.coli XL1-Blue 
10µl of ligation reaction was mixed with 50µl of chemocompetent E.coli XL1-Blue, 
incubated for 5min on ice, heat-shocked at 42°C for  30s and incubated once more for 
5min on ice. Cells were then suspended in 1ml LB medium and incubated for 1h at 
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37°C and 750rpm. Afterwards transformants were sele cted on LB agar plates 
containing appropriate antibiotics and analyzed via Colony-check PCR (see 7.10). 
 
7.10 Colony-check PCR 
Colony-check PCR was used to screen bacterial colonies for the presence of a 
transformed plasmid. Total DNA contained in bacterial colony served as template. 
PCR was carried out using standard PCR parameters (see 7.3).  
 
7.11 Purification of plasmid DNA 
Extraction of plasmid DNA was performed using the Nucleobond AX Kit from 
Macherey-Nagel according to manufacturer’s protocol. 
 
7.12 Quantification of nucleic acids 
Amount and purity of nucleic acids were determined using NanoDrop ND-1000 




Sequencing of plasmid DNA was performed by GATC Biotech and SeqLab using 
chain terminator method (Sanger et al. 1977).  
 
7.14 Cultivation of eukaryotic COS7 or HEK cells 
COS7 cells are adherent African green monkey kidney fibroblasts and HEK cells are 
human embryonic kidney cells. Cells were cultivated in DMEM-medium containing 
10% FCS as well as 1% P/S (penicillin/streptomycin) and were grown at 37°C, 5% 
CO2 and 100% humidity in a cell incubator. For passaging, cells were detached using 
Trypsin-EDTA and splitted 1:10 or 1:100. 
 
7.15 Transfection of eukaryotic cells 
The transfection of COS7 as well as HEK cells was performed using TurboFect 
transfection reagent (Fermentas). One day before transfection, 500,000 cells were 
sown on a 6-well plate and grown for 24h at 37°C, 5 % CO2 and 100% humidity. Next 
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day, 1µg DNA and 2µl TurboFect Transfection Reagent were mixed in 200µl 
serum-free DMEM-medium, incubated for 15min at room temperature and distributed 
to the bottom of each well. The transgene expression was analyzed after 48 hours by 
fluorescence microscopy or western blot. 
 
7.16 Sodium dodecyl sulfate polyacrylamide gel elec trophoresis 
(SDS-PAGE) 
SDS-PAGE is a method to separate proteins according to their electrophoretic 
mobility and allows the analysis of proteins via staining or Western blotting. 
Furthermore, molecular weight of analyzed proteins can be determined using 
molecular weight marker. 
Proteins were separated by discontinous gel electrophoresis. Compositions of the 
different gels are shown in Tab. 7-2. Electrophoresis was performed in 1x SDS-
running buffer. Protein samples were supplemented with 4x SDS-loading dye and 
loaded onto the gel. Electrophoresis was carried out at 120-180V for 90 to 120min. 
 
Tab. 7-2: Gel components for SDS-PAGE 




Milli Q H2O 1860 750 
1.5M Tris/HCl, pH 8.8 - 850 
0.5M Tris/HCl, pH 6.8 310 - 
10% SDS 25 33 
Polyacrylamide 330 1650 
10% APS 25 33 
TEMED 5 3 
 
7.17 Western Blot 
Proteins separated by SDS-PAGE were transferred to PVDF-membrane using semi-
dry blotting (60 min, 3-4mA/cm2). The membrane was blocked with TBST 
supplemented with BSA or milk powder (dependent on the primary antibody) for 1h. 
After washing with TBST membrane was incubated with primary antibody over-night 
at 4°C. Washed membranes were incubated with second ary antibody for 1h at room 
temperature. Unbound antibodies were washed away with TBST. Membranes were 
developed using the ECL-detection solution (GE Healthcare) and signals were 
detected using chemiluminescent FluorChemQ imaging system (AlphaInnotech). 
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7.18 Animal treatment 
All experiments were performed according to German guidelines for animal care and 
protection (V742-72 241.121-3 (20-2/04) and (76-7/00) as well as V312-72241.121-
3). Mice were maintained in a 12h light-dark cycle under standard conditions and 
were provided with food and water ad libitum. All animals were pathogen free as 
assessed by regular microbiological screening and kept under barrier conditions at 
21°C ± 2°C and 60% ± 5% humidity in individually ventilated cages. 
 
7.19 Induction of DSS-colitis and determination of clinical scores 
Colitis was induced by administration of 2% dextran sulfate sodium (DSS) in the 
drinking water for 5d followed by 5d of regular drinking water or by administration of 
2% DSS for 7d.  Groups of four to six mice were used to monitor the disease activity 
index (DAI, see Tab. 7-3). Body weight and fecal blood loss using the hemoccult test 
were recorded daily. DAI displaying the combined score of weight loss, rectal 
bleeding and histology was performed as previously described by Siegmund et al. 
2001 and Grivennikov et al. 2009. A high resolution mouse video endoscopic system 
was used (HOPKINS® Optik 64019BA; KARL STOLZ AIDATM VET, Berlin, Germany) 
and murine endoscopic score of colitis severity (MEICS, see Tab. 7-3) were obtained 
as described by Fantini et al. (2006).  
 
Tab. 7-3: Components of DAI and MEICS 
Disease Activity Index Murine Endoscopic Score of 
Colitis Severity (MEICS) 
Weight loss Inflammatory signs in colonoscopy 
Rectal bleeding  
Histology  
 
7.20 Colon organ culture  
A segment of the distal colon was removed, cut open longitudinally and washed in 
PBS. Colon segments were then further cut into pieces of 1cm2 and incubated in 6-
well culture dish containing 2ml fresh DMEM medium supplemented with penicillin 
and streptomycin at 37°C for 24h. Culture supernata nts were harvested and assayed 
for KC, MCP-1, IL-10, IL-11, IL-12, IL-21, IL-17 and IFN-γ levels by ELISA (R&D 
Systems, Wiesbaden, Germany) according to the manufacturer’s protocols. Optical 
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densities were measured at 450nm using ELISA plate reader (SLT Rainbow, Tecan, 
Maennedorf, Switzerland) and were evaluated using a standard curve. 
 
7.21 Myeloperoxidase activity measurement 
Myeloperoxidase (MPO) activity was measured in colon tissue taken from the distal 
colon. After freezing in liquid nitrogen, equal aliquots of tissue samples (30µl 
buffer/mg colon tissue) were homogenized in MPO buffer, incubated at 60°C for 2h 
and centrifuged for 5min at 10,000rpm. 10µl of the supernatant were mixed with 50µl 
peroxidase substrate. After 20min 50µl of H2SO4 were added to stop the reaction and 
the absorbance was measured at 450nm on a SLT Rainbow plate reader (Tecan, 
Maennedorf, Switzerland) and evaluated using a standard curve. 
 
7.22 FITC dextran and BrdU administration 
Intestinal permeability was assessed by administration of the non-metabolizable 
macromolecule FITC-dextran 4000 (Sigma-Aldrich, Deisenhofen, Germany). FITC-
dextran was administered by gavage (0.6g/kg body weight) 4h before sacrifice. 
Whole blood and serum were obtained by cardiac puncture and centrifugation at 
5,000rpm for 15min respectively. Dilutions of FITC-dextran 4,000 in PBS were used 
as a standard curve and absorption of 100µl serum or standard was measured in a 
fluorometer at 488nm. To study proliferation of epithelial cells 50mg BrdU/kg body 
weight (CalBiochem, Schwalbach, Germany) was injected intraperitoneally 2h before 
sacrifice. 
 
7.23 Statistical analysis 
All parametric data are presented as the means ± standard deviation. Data from two 
groups were analyzed for significance using a student’s unpaired t-test 
(http://www.physics.csbsju.edu/stats/t-test.html). Differences were considered as 
statistically significant if p ≤ 0.05.  
 
7.24 Immunohistochemistry (IHC) 
7.24.1 Processing of tissues 
Colon tissue, especially the distal part, was removed and fixed in 4% 
paraformaldehyde in 1xPBS for 24h. Tissues were dehydrated in an ascending 
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ethanol and xylol series. Samples were embedded in paraffin and dissected with 5µm 
using a microtome (Leica RM2165). 
For cryosections the last third of the colon was frozen with tissue freezing medium 
(Jung) in liquid nitrogen and dissected with 6µM using cryomicrotome (Leica 
CM3050S). 
 
7.24.2 HE staining 
Processed tissue sections were incubated in Shadon Gill III Hematoxylin, 
differentiated in 0.5% acetic acid, washed and stained with Giemsa’s azur eosin 
methylen blue solution. The stained sections were analyzed by microscopy. 
 
7.24.3 BrdU staining 
To visualize BrdU incorporation sections were stained with 1:500 dilution of mouse 
anti-BrdU mAb in Antibody Diluent over night. Sections were then incubated for 1h 
with biotinylated anti-mouse secondary antibody (1:50 in Antibody Diluent) and 
developed with AEC substrate. Counterstaining was performed with Shadon Gill III 
Hemytoxylin. Stained sections were analyzed by microscopy. 
 
7.24.4 Immunofluorescence staining 
Processed cryosections were fixed in ice-cold acetone for 10min followed by 
sequential incubation with blocking reagent. Slides were then incubated for 1h at 
room temperature with α-CD3 or α-CD68 (1:50 or 1:100 in Antibody Diluent). After 
washing with PBS, slides were incubated for 45min at room temperature with Cy3- or 
FITC-labeled secondary antibodies. Nuclei were counterstained with DAPI 
(20mg/ml). 
 
7.25 Isolation of spleen cells from C57BL/6N mice 
Spleen was isolated from C57BL/6N mice and passed through a nylon mash into a 
50ml tube containing 10ml RPMI-medium supplemented with 25mM NaHCO3, 2mM 
glutamine, 1% penicillin/streptomycin and 10mM HEPES. The cell suspension was 
centrifuged at 1,300rpm for 5min at room temperature. The cell pellet was 
resupended with erythrocytes lysis buffer, incubated for 3min at room temperature 
and centrifuged again at 1,300rpm for 5min. The supernatant was discarded and 
cells were resuspended in 1ml RPMI-medium and counted using Neubauer counting 
chamber. 
Methods 58 
7.26 Cell stimulation 
7.26.1 Spleen cells 
Isolated spleen cells were stimulated with BzATP (300µM), GI (ADAM10 inhibitor) or 
GW (ADAM10+17 inhibitor). 4x106 spleen cells were sown in a 96 well plate and 
incubated with 3µM inhibitor at 37°C 30min before s timulation with BzATP. Cells 
were centrifuged for 10min at 1,500rpm after 20min of BzATP stimulation, 
resuspended in FACS-buffer and used for FACS analysis. 
 
7.26.2 COS7 or HEK cells 
Transfected COS7 or HEK cells were pretreated with GI (ADAM10 inhibitor) for 
30min at 37°C and afterwards stimulated 30min with ionomycin (2,5µM) at 37°C. 
After stimulation, cells were detached from a 6well plate with 1ml FACS-buffer 
containing 2mM EDTA and counted using Neubauer counting chamber.  
 
7.27 Fluorescence activated cell sorting (FACS) 
7.27.1 Spleen cells 
For FACS staining 106 stimulated cells were used. Cells were blocked with 0.25µl Fc-
Block solution and 1µl rat serum for 30min on ice. Staining occurred with APC 
hamster anti-mouse CD3e, PE hamster anti-mouse CD27, FITC rat anti-mouse 
B220, FITC mouse anti-rat CD4 or PE rat anti-mouse CD62L (diluted 1:400 in 100µl 
FACS-buffer) for 30min at room temperature under dark conditions. Cells were 
centrifuged for 5min at 3,700rpm and 4°C, resupende d in 500µl FACS-buffer and 
analyzed by flow cytometry. 
 
7.28 Alkaline phosphatase (AP) analysis 
Transiently transfected COS7 or HEK cells with alkaline phosphatase (AP) constructs 
were analyzed 48h after transfection. Therefore, cells were stimulated with either 
ionomycin or ionomycin and GI as described in 7.25. Supernatant of cells was 
collected, centrifuged at 13,000rpm for 30min and 4°C and afterwards used for AP 
analysis. Cells were harvested with 1xPBS, centrifuged (1min, 13,000rpm), 
resupended in 75µl lysis buffer and incubated for 1h at 4°C. Afterwards, cell lysate 
was centrifuged for 30min at 4°C and the supernatan t was used for AP analysis. 5µl 
of lysate and 50µl of supernatant was loaded on a 96well dish together with controls 
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and added with 50µl AP substrate. AP activity was measured at 405nm and ratio of 
supernatant and lysate AP activity was calculated. 
 
7.29 Transgenic animals  
7.29.1 Generation and characterization of hypomorph ic ADAM17 ex/ex mice 
ADAM17ex/ex mice were generated in our group as described in section 2.1. DNA was 
isolated from mouse tails using Puregene Tissue Core Kit A according to the 
manufacturer’s protocol. Afterwards the ADAM17 transcripts were amplified by PCR 
(7.3.1) using primers 3’floxADAM17geno and 5’floxADAM17geno (Tab. 6-1). PCR 
was performed with the following PCR program: 95°C 5min, 35x (95°C 1min, 52°C 
1min, 72°C 1min), 72°C 5min. PCR products were anal yzed by agarose 
gelelectrophoresis. PCR products of 550bp, 380bp or both were amplified from 
























Akiba, H., H. Nakano, S. Nishinaka, M. Shindo, T. Kobata, M. Atsuta, C. Morimoto, 
C. F. Ware, N. L. Malinin, D. Wallach, H. Yagita and K. Okumura (1998). 
"CD27, a member of the tumor necrosis factor receptor superfamily, activates 
NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via 
TRAF2, TRAF5, and NF-kappaB-inducing kinase." J Biol Chem 273(21): 
13353-8. 
Alonzi, T., I. P. Newton, P. J. Bryce, E. Di Carlo, G. Lattanzio, M. Tripodi, P. Musiani 
and V. Poli (2004). "Induced somatic inactivation of STAT3 in mice triggers the 
development of a fulminant form of enterocolitis." Cytokine 26(2): 45-56. 
Amano, A., I. Nakagawa and T. Yoshimori (2006). "Autophagy in innate immunity 
against intracellular bacteria." J Biochem 140(2): 161-6. 
Arribas, J., L. Coodly, P. Vollmer, T. K. Kishimoto, S. Rose-John and J. Massague 
(1996). "Diverse cell surface protein ectodomains are shed by a system 
sensitive to metalloprotease inhibitors." J Biol Chem 271(19): 11376-82. 
Atreya, R., J. Mudter, S. Finotto, J. Mullberg, T. Jostock, S. Wirtz, M. Schutz, B. 
Bartsch, M. Holtmann, C. Becker, D. Strand, J. Czaja, J. F. Schlaak, H. A. 
Lehr, F. Autschbach, G. Schurmann, N. Nishimoto, K. Yoshizaki, H. Ito, T. 
Kishimoto, P. R. Galle, S. Rose-John and M. F. Neurath (2000). "Blockade of 
interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in 
chronic intestinal inflammation: evidence in crohn disease and experimental 
colitis in vivo." Nat Med 6(5): 583-8. 
Auernhammer, C. J., K. Zitzmann, F. Schnitzler, J. Seiderer, P. Lohse, G. Vlotides, 
D. Engelhardt, M. Sackmann, B. Goke and T. Ochsenkuhn (2005). "Role of 
the intracellular receptor domain of gp130 (exon 17) in human inflammatory 
bowel disease." World J Gastroenterol 11(8): 1196-9. 
Becker, C., M. C. Fantini, S. Wirtz, A. Nikolaev, H. A. Lehr, P. R. Galle, S. Rose-John 
and M. F. Neurath (2005). "IL-6 signaling promotes tumor growth in colorectal 
cancer." Cell Cycle 4(2): 217-20. 
Bigler, R. D., Y. Bushkin and N. Chiorazzi (1988). "S152 (CD27). A modulating 
disulfide-linked T cell activation antigen." J Immunol 141(1): 21-8. 
Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, 
B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K. 
A. Schooley, M. Gerhart, R. Davis, J. N. Fitzner, R. S. Johnson, R. J. Paxton, 
C. J. March and D. P. Cerretti (1997). "A metalloproteinase disintegrin that 
releases tumour-necrosis factor-alpha from cells." Nature 385(6618): 729-33. 
Blobel, C. P. (2005). "ADAMs: key components in EGFR signalling and 
development." Nat Rev Mol Cell Biol 6(1): 32-43. 
Bollrath, J., T. J. Phesse, V. A. von Burstin, T. Putoczki, M. Bennecke, T. Bateman, 
T. Nebelsiek, T. Lundgren-May, O. Canli, S. Schwitalla, V. Matthews, R. M. 
Schmid, T. Kirchner, M. C. Arkan, M. Ernst and F. R. Greten (2009). "gp130-
References 61 
mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle 
progression during colitis-associated tumorigenesis." Cancer Cell 15(2): 91-
102. 
Borst, J., J. Hendriks and Y. Xiao (2005). "CD27 and CD70 in T cell and B cell 
activation." Curr Opin Immunol 17(3): 275-81. 
Boyer, J. L. and T. K. Harden (1989). "Irreversible activation of phospholipase C-
coupled P2Y-purinergic receptors by 3'-O-(4-benzoyl)benzoyl adenosine 5'-
triphosphate." Mol Pharmacol 36(6): 831-5. 
Breckwoldt, M. O., J. W. Chen, L. Stangenberg, E. Aikawa, E. Rodriguez, S. Qiu, M. 
A. Moskowitz and R. Weissleder (2008). "Tracking the inflammatory response 
in stroke in vivo by sensing the enzyme myeloperoxidase." Proc Natl Acad Sci 
U S A 105(47): 18584-9. 
Chalaris, A., N. Adam, C. Sina, P. Rosenstiel, J. Lehmann, P. Schirmacher, D. 
Hartmann, J. Cichy, O. Gavrilova, S. Schreiber, T. Jostock, V. Matthews, R. 
Häsler, C. Becker, M. F. Neurath, K. Reiß, P. Saftig, J. Scheller and S. Rose-
John (accepted). "Critical Role of the Disintegrin Metalloprotease ADAM17 for 
Intestinal Inflammation and Regeneration in Mice." Journal of Experimental 
Medicine. 
Cho, J. H. and C. T. Weaver (2007). "The genetics of inflammatory bowel disease." 
Gastroenterology 133(4): 1327-39. 
Derouet, D., F. Rousseau, F. Alfonsi, J. Froger, J. Hermann, F. Barbier, D. Perret, C. 
Diveu, C. Guillet, L. Preisser, A. Dumont, M. Barbado, A. Morel, O. 
deLapeyriere, H. Gascan and S. Chevalier (2004). "Neuropoietin, a new IL-6-
related cytokine signaling through the ciliary neurotrophic factor receptor." 
Proc Natl Acad Sci U S A 101(14): 4827-32. 
Dieleman, L. A., B. U. Ridwan, G. S. Tennyson, K. W. Beagley, R. P. Bucy and C. O. 
Elson (1994). "Dextran sulfate sodium-induced colitis occurs in severe 
combined immunodeficient mice." Gastroenterology 107(6): 1643-52. 
Dillon, S. R., C. Sprecher, A. Hammond, J. Bilsborough, M. Rosenfeld-Franklin, S. R. 
Presnell, H. S. Haugen, M. Maurer, B. Harder, J. Johnston, S. Bort, S. Mudri, 
J. L. Kuijper, T. Bukowski, P. Shea, D. L. Dong, M. Dasovich, F. J. Grant, L. 
Lockwood, S. D. Levin, C. LeCiel, K. Waggie, H. Day, S. Topouzis, J. Kramer, 
R. Kuestner, Z. Chen, D. Foster, J. Parrish-Novak and J. A. Gross (2004). 
"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in 
mice." Nat Immunol 5(7): 752-60. 
Edwards, D. R., M. M. Handsley and C. J. Pennington (2008). "The ADAM 
metalloproteinases." Mol Aspects Med 29(5): 258-89. 
Egger, B., H. V. Carey, F. Procaccino, N. N. Chai, E. P. Sandgren, J. Lakshmanan, 
V. S. Buslon, S. W. French, M. W. Buchler and V. E. Eysselein (1998). 
"Reduced susceptibility of mice overexpressing transforming growth factor 
alpha to dextran sodium sulphate induced colitis." Gut 43(1): 64-70. 
Egger, B., F. Procaccino, J. Lakshmanan, M. Reinshagen, P. Hoffmann, A. Patel, W. 
Reuben, S. Gnanakkan, L. Liu, L. Barajas and V. E. Eysselein (1997). "Mice 
References 62 
lacking transforming growth factor alpha have an increased susceptibility to 
dextran sulfate-induced colitis." Gastroenterology 113(3): 825-32. 
Elliott, M. J., R. N. Maini, M. Feldmann, A. Long-Fox, P. Charles, P. Katsikis, F. M. 
Brennan, J. Walker, H. Bijl, J. Ghrayeb and J. N. Woody (1993). "Treatment of 
rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis 
factor alpha." Arthritis Rheum 36(12): 1681-90. 
Franke, A., T. Balschun, T. H. Karlsen, J. Hedderich, S. May, T. Lu, D. Schuldt, S. 
Nikolaus, P. Rosenstiel, M. Krawczak and S. Schreiber (2008). "Replication of 
signals from recent studies of Crohn's disease identifies previously unknown 
disease loci for ulcerative colitis." Nat Genet 40(6): 713-5. 
Garcia, P., A. B. De Heredia, T. Bellon, E. Carpio, M. Llano, E. Caparros, P. Aparicio 
and M. Lopez-Botet (2004). "Signalling via CD70, a member of the TNF family, 
regulates T cell functions." J Leukoc Biol 76(1): 263-70. 
Grivennikov, S., E. Karin, J. Terzic, D. Mucida, G. Y. Yu, S. Vallabhapurapu, J. 
Scheller, S. Rose-John, H. Cheroutre, L. Eckmann and M. Karin (2009). "IL-6 
and Stat3 are required for survival of intestinal epithelial cells and 
development of colitis-associated cancer." Cancer Cell 15(2): 103-13. 
Gu, H., J. C. Pratt, S. J. Burakoff and B. G. Neel (1998). "Cloning of p97/Gab2, the 
major SHP2-binding protein in hematopoietic cells, reveals a novel pathway 
for cytokine-induced gene activation." Mol Cell 2(6): 729-40. 
Hampe, J., A. Franke, P. Rosenstiel, A. Till, M. Teuber, K. Huse, M. Albrecht, G. 
Mayr, F. M. De La Vega, J. Briggs, S. Gunther, N. J. Prescott, C. M. Onnie, R. 
Hasler, B. Sipos, U. R. Folsch, T. Lengauer, M. Platzer, C. G. Mathew, M. 
Krawczak and S. Schreiber (2007). "A genome-wide association scan of 
nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in 
ATG16L1." Nat Genet 39(2): 207-11. 
Hampe, J., H. Frenzel, M. M. Mirza, P. J. Croucher, A. Cuthbert, S. Mascheretti, K. 
Huse, M. Platzer, S. Bridger, B. Meyer, P. Nurnberg, P. Stokkers, M. 
Krawczak, C. G. Mathew, M. Curran and S. Schreiber (2002). "Evidence for a 
NOD2-independent susceptibility locus for inflammatory bowel disease on 
chromosome 16p." Proc Natl Acad Sci U S A 99(1): 321-6. 
Hartmann, D., B. de Strooper, L. Serneels, K. Craessaerts, A. Herreman, W. 
Annaert, L. Umans, T. Lubke, A. Lena Illert, K. von Figura and P. Saftig 
(2002). "The disintegrin/metalloprotease ADAM 10 is essential for Notch 
signalling but not for alpha-secretase activity in fibroblasts." Hum Mol Genet 
11(21): 2615-24. 
Hassemer, E. L., S. M. Le Gall, R. Liegel, M. McNally, B. Chang, C. J. Zeiss, R. D. 
Dubielzig, K. Horiuchi, T. Kimura, Y. Okada, C. P. Blobel and D. J. Sidjanin 
(2010). "The waved with open eyelids (woe) Locus is a Hypomorphic Mouse 
Mutation in Adam17." Genetics DOI:10.1534/genetics.109.113167 . 
Heinrich, P. C., I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen and F. 
Schaper (2003). "Principles of interleukin (IL)-6-type cytokine signalling and its 
regulation." Biochem J 374(Pt 1): 1-20. 
References 63 
Heinrich, P. C., I. Behrmann, G. Muller-Newen, F. Schaper and L. Graeve (1998). 
"Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway." 
Biochem J 334 (Pt 2): 297-314. 
Hirano, T., T. Taga, N. Nakano, K. Yasukawa, S. Kashiwamura, K. Shimizu, K. 
Nakajima, K. H. Pyun and T. Kishimoto (1985). "Purification to homogeneity 
and characterization of human B-cell differentiation factor (BCDF or BSFp-2)." 
Proc Natl Acad Sci U S A 82(16): 5490-4. 
Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. 
Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. 
Sakiyama, H. Matsui, Y. Takahara, T. Taniguchi and T. Kishimoto (1986). 
"Complementary DNA for a novel human interleukin (BSF-2) that induces B 
lymphocytes to produce immunoglobulin." Nature 324(6092): 73-6. 
Holgado-Madruga, M., D. R. Emlet, D. K. Moscatello, A. K. Godwin and A. J. Wong 
(1996). "A Grb2-associated docking protein in EGF- and insulin-receptor 
signalling." Nature 379(6565): 560-4. 
Horiuchi, K., T. Kimura, T. Miyamoto, K. Miyamoto, H. Akiyama, H. Takaishi, H. 
Morioka, T. Nakamura, Y. Okada, C. P. Blobel and Y. Toyama (2009). 
"Conditional inactivation of TACE by a Sox9 promoter leads to osteoporosis 
and increased granulopoiesis via dysregulation of IL-17 and G-CSF." J 
Immunol 182(4): 2093-101. 
Horiuchi, K., T. Kimura, T. Miyamoto, H. Takaishi, Y. Okada, Y. Toyama and C. P. 
Blobel (2007). "Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) 
inactivation in mouse myeloid cells prevents lethality from endotoxin shock." J 
Immunol 179(5): 2686-9. 
Horiuchi, K., H. M. Zhou, K. Kelly, K. Manova and C. P. Blobel (2005). "Evaluation of 
the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and 
ectodomain shedding of neuregulins beta1 and beta2." Dev Biol 283(2): 459-
71. 
Hugot, J. P., M. Chamaillard, H. Zouali, S. Lesage, J. P. Cezard, J. Belaiche, S. 
Almer, C. Tysk, C. A. O'Morain, M. Gassull, V. Binder, Y. Finkel, A. Cortot, R. 
Modigliani, P. Laurent-Puig, C. Gower-Rousseau, J. Macry, J. F. Colombel, M. 
Sahbatou and G. Thomas (2001). "Association of NOD2 leucine-rich repeat 
variants with susceptibility to Crohn's disease." Nature 411(6837): 599-603. 
Irie-Sasaki, J., T. Sasaki, W. Matsumoto, A. Opavsky, M. Cheng, G. Welstead, E. 
Griffiths, C. Krawczyk, C. D. Richardson, K. Aitken, N. Iscove, G. Koretzky, P. 
Johnson, P. Liu, D. M. Rothstein and J. M. Penninger (2001). "CD45 is a JAK 
phosphatase and negatively regulates cytokine receptor signalling." Nature 
409(6818): 349-54. 
Ito, H. (2005). "Treatment of Crohn's disease with anti-IL-6 receptor antibody." J 
Gastroenterol 40 32-4. 
Jenkins, B. J., D. Grail, T. Nheu, M. Najdovska, B. Wang, P. Waring, M. Inglese, R. 
M. McLoughlin, S. A. Jones, N. Topley, H. Baumann, L. M. Judd, A. S. Giraud, 
A. Boussioutas, H. J. Zhu and M. Ernst (2005). "Hyperactivation of Stat3 in 
References 64 
gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-
beta signaling." Nat Med 11(8): 845-52. 
Jones, S. A., D. Novick, S. Horiuchi, N. Yamamoto, A. J. Szalai and G. M. Fuller 
(1999). "C-reactive protein: a physiological activator of interleukin 6 receptor 
shedding." J Exp Med 189(3): 599-604. 
Jones, S. A., P. J. Richards, J. Scheller and S. Rose-John (2005). "IL-6 
transsignaling: the in vivo consequences." J Interferon Cytokine Res 25(5): 
241-53. 
Jostock, T., J. Mullberg, S. Ozbek, R. Atreya, G. Blinn, N. Voltz, M. Fischer, M. F. 
Neurath and S. Rose-John (2001). "Soluble gp130 is the natural inhibitor of 
soluble interleukin-6 receptor transsignaling responses." Eur J Biochem 
268(1): 160-7. 
Kaser, A., A. H. Lee, A. Franke, J. N. Glickman, S. Zeissig, H. Tilg, E. E. 
Nieuwenhuis, D. E. Higgins, S. Schreiber, L. H. Glimcher and R. S. Blumberg 
(2008). "XBP1 links ER stress to intestinal inflammation and confers genetic 
risk for human inflammatory bowel disease." Cell 134(5): 743-56. 
Kenny, P. A. (2007). "TACE: a new target in epidermal growth factor receptor 
dependent tumors." Differentiation 75(9): 800-8. 
Ketteler, R., S. Glaser, O. Sandra, U. M. Martens and U. Klingmuller (2002). 
"Enhanced transgene expression in primitive hematopoietic progenitor cells 
and embryonic stem cells efficiently transduced by optimized retroviral hybrid 
vectors." Gene Ther 9(8): 477-87. 
Kishimoto, T. (2010). "IL-6: from its discovery to clinical applications." Int Immunol 
22(5): 347-52. 
Loenen, W. A., E. De Vries, L. A. Gravestein, R. Q. Hintzen, R. A. Van Lier and J. 
Borst (1992). "The CD27 membrane receptor, a lymphocyte-specific member 
of the nerve growth factor receptor family, gives rise to a soluble form by 
protein processing that does not involve receptor endocytosis." Eur J Immunol 
22(2): 447-55. 
Long, C., Y. Wang, A. H. Herrera, K. Horiuchi Dagger and B. Walcheck (2010). "In 
vivo role of leukocyte ADAM17 in the inflammatory and host responses during 
E. coli-mediated peritonitis." J Leukoc Biol DOI: 10.1189/jlb.1109763 . 
Ludwig, A., C. Hundhausen, M. H. Lambert, N. Broadway, R. C. Andrews, D. M. 
Bickett, M. A. Leesnitzer and J. D. Becherer (2005). "Metalloproteinase 
inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 
that differentially block constitutive and phorbol ester-inducible shedding of cell 
surface molecules." Comb Chem High Throughput Screen 8(2): 161-71. 
Luedde, T., C. Liedtke, M. P. Manns and C. Trautwein (2002). "Losing balance: 
cytokine signaling and cell death in the context of hepatocyte injury and 
hepatic failure." Eur Cytokine Netw 13(4): 377-83. 
References 65 
Lust, J. A., K. A. Donovan, M. P. Kline, P. R. Greipp, R. A. Kyle and N. J. Maihle 
(1992). "Isolation of an mRNA encoding a soluble form of the human 
interleukin-6 receptor." Cytokine 4(2): 96-100. 
Manocha, M., S. Rietdijk, A. Laouar, G. Liao, A. Bhan, J. Borst, C. Terhorst and N. 
Manjunath (2009). "Blocking CD27-CD70 costimulatory pathway suppresses 
experimental colitis." J Immunol 183(1): 270-6. 
Matsumoto, S., T. Hara, K. Mitsuyama, M. Yamamoto, O. Tsuruta, M. Sata, J. 
Scheller, S. Rose-John, S. Kado and T. Takada (2010). "Essential roles of IL-6 
trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 
receptor derived from lamina propria macrophages, on the development of 
colitis-associated premalignant cancer in a murine model." J Immunol 184(3): 
1543-51. 
Matthews, V., B. Schuster, S. Schutze, I. Bussmeyer, A. Ludwig, C. Hundhausen, T. 
Sadowski, P. Saftig, D. Hartmann, K. J. Kallen and S. Rose-John (2003). 
"Cellular cholesterol depletion triggers shedding of the human interleukin-6 
receptor by ADAM10 and ADAM17 (TACE)." J Biol Chem 278(40): 38829-39. 
Maxwell, J. R. and J. L. Viney (2009). "Overview of Mouse Models of Inflammatory 
bowel disease and their use in drug discovery." Current Protocols in 
Pharmacology 47: 5.57.1-5.57.19. 
McGowan, P. M., E. McKiernan, F. Bolster, B. M. Ryan, A. D. K. Hill, E. W. 
McDermott, D. Evoy, N. O'Higgins, J. Crown and M. J. Duffy (2007). "ADAM17 
predicts adverse outcome in patients with breast cancer." AnnOncol 19(6): 
1070-1081. 
Mitsuyama, K., S. Matsumoto, S. Rose-John, A. Suzuki, T. Hara, N. Tomiyasu, K. 
Handa, O. Tsuruta, H. Funabashi, J. Scheller, A. Toyonaga and M. Sata 
(2006). "STAT3 activation via interleukin 6 trans-signalling contributes to ileitis 
in SAMP1/Yit mice." Gut 55(9): 1263-9. 
Mitsuyama, K., E. Sasaki, A. Toyonaga, H. Ikeda, O. Tsuruta, A. Irie, N. Arima, T. 
Oriishi, K. Harada and K. Fujisaki (1991). "Colonic mucosal interleukin-6 in 
inflammatory bowel disease." Digestion 50(2): 104-11. 
Mitsuyama, K., A. Toyonaga, E. Sasaki, O. Ishida, H. Ikeda, O. Tsuruta, K. Harada, 
H. Tateishi, T. Nishiyama and K. Tanikawa (1995). "Soluble interleukin-6 
receptors in inflammatory bowel disease: relation to circulating interleukin-6." 
Gut 36(1): 45-9. 
Moon, H., H. Y. Na, K. H. Chong and T. J. Kim (2006). "P2X7 receptor-dependent 
ATP-induced shedding of CD27 in mouse lymphocytes." Immunol Lett 102(1): 
98-105. 
Moss, M. L. and J. W. Bartsch (2004). "Therapeutic benefits from targeting of ADAM 
family members." Biochemistry 43(23): 7227-35. 
Moss, M. L., S. L. Jin, M. E. Milla, D. M. Bickett, W. Burkhart, H. L. Carter, W. J. 
Chen, W. C. Clay, J. R. Didsbury, D. Hassler, C. R. Hoffman, T. A. Kost, M. H. 
Lambert, M. A. Leesnitzer, P. McCauley, G. McGeehan, J. Mitchell, M. Moyer, 
G. Pahel, W. Rocque, L. K. Overton, F. Schoenen, T. Seaton, J. L. Su and J. 
References 66 
D. Becherer (1997). "Cloning of a disintegrin metalloproteinase that processes 
precursor tumour-necrosis factor-alpha." Nature 385(6618): 733-6. 
Moss, M. L., L. Sklair-Tavron and R. Nudelman (2008). "Drug insight: tumor necrosis 
factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis." 
Nat Clin Pract Rheumatol 4(6): 300-9. 
Mullberg, J., K. Althoff, T. Jostock and S. Rose-John (2000). "The importance of 
shedding of membrane proteins for cytokine biology." Eur Cytokine Netw 
11(1): 27-38. 
Mullberg, J., F. H. Durie, C. Otten-Evans, M. R. Alderson, S. Rose-John, D. Cosman, 
R. A. Black and K. M. Mohler (1995). "A metalloprotease inhibitor blocks 
shedding of the IL-6 receptor and the p60 TNF receptor." J Immunol 155(11): 
5198-205. 
Muller-Newen, G., A. Kuster, U. Hemmann, R. Keul, U. Horsten, A. Martens, L. 
Graeve, J. Wijdenes and P. C. Heinrich (1998). "Soluble IL-6 receptor 
potentiates the antagonistic activity of soluble gp130 on IL-6 responses." J 
Immunol 161(11): 6347-55. 
Murphy, G. (2008). "The ADAMs: signalling scissors in the tumour 
microenvironment." Nat Rev Cancer 8(12): 929-41. 
Murray, P. J. (2005). "The primary mechanism of the IL-10-regulated 
antiinflammatory response is to selectively inhibit transcription." Proc Natl 
Acad Sci U S A 102(24): 8686-91. 
Naka, T., N. Nishimoto and T. Kishimoto (2002). "The paradigm of IL-6: from basic 
science to medicine." Arthritis Res 4 S233-42. 
Neron, S., G. Suck, X. Z. Ma, D. Sakac, A. Roy, Y. Katsman, N. Dussault, C. Racine 
and D. R. Branch (2006). "B cell proliferation following CD40 stimulation 
results in the expression and activation of Src protein tyrosine kinase." Int 
Immunol 18(2): 375-87. 
Nicholson, S. E., T. A. Willson, A. Farley, R. Starr, J. G. Zhang, M. Baca, W. S. 
Alexander, D. Metcalf, D. J. Hilton and N. A. Nicola (1999). "Mutational 
analyses of the SOCS proteins suggest a dual domain requirement but distinct 
mechanisms for inhibition of LIF and IL-6 signal transduction." Embo J 18(2): 
375-85. 
Nolte, M. A., R. W. van Olffen, K. P. van Gisbergen and R. A. van Lier (2009). 
"Timing and tuning of CD27-CD70 interactions: the impact of signal strength in 
setting the balance between adaptive responses and immunopathology." 
Immunol Rev 229(1): 216-31. 
Ogura, Y., D. K. Bonen, N. Inohara, D. L. Nicolae, F. F. Chen, R. Ramos, H. Britton, 
T. Moran, R. Karaliuskas, R. H. Duerr, J. P. Achkar, S. R. Brant, T. M. 
Bayless, B. S. Kirschner, S. B. Hanauer, G. Nunez and J. H. Cho (2001). "A 
frameshift mutation in NOD2 associated with susceptibility to Crohn's 
disease." Nature 411(6837): 603-6. 
References 67 
Okayasu, I., S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki and R. Nakaya 
(1990). "A novel method in the induction of reliable experimental acute and 
chronic ulcerative colitis in mice." Gastroenterology 98(3): 694-702. 
Peschon, J. J., J. L. Slack, P. Reddy, K. L. Stocking, S. W. Sunnarborg, D. C. Lee, 
W. E. Russell, B. J. Castner, R. S. Johnson, J. N. Fitzner, R. W. Boyce, N. 
Nelson, C. J. Kozlosky, M. F. Wolfson, C. T. Rauch, D. P. Cerretti, R. J. 
Paxton, C. J. March and R. A. Black (1998). "An essential role for ectodomain 
shedding in mammalian development." Science 282(5392): 1281-4. 
Peters, M., A. M. Muller and S. Rose-John (1998). "Interleukin-6 and soluble 
interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis." Blood 
92(10): 3495-504. 
Pflanz, S., L. Hibbert, J. Mattson, R. Rosales, E. Vaisberg, J. F. Bazan, J. H. Phillips, 
T. K. McClanahan, R. de Waal Malefyt and R. A. Kastelein (2004). "WSX-1 
and glycoprotein 130 constitute a signal-transducing receptor for IL-27." J 
Immunol 172(4): 2225-31. 
Podolsky, D. K. (2002). "Inflammatory bowel disease." N Engl J Med 347(6): 417-29. 
Pruessmeyer, J. and A. Ludwig (2009). "The good, the bad and the ugly substrates 
for ADAM10 and ADAM17 in brain pathology, inflammation and cancer." 
Semin Cell Dev Biol 20(2): 164-74. 
Rabe, B., A. Chalaris, U. May, G. H. Waetzig, D. Seegert, A. S. Williams, S. A. 
Jones, S. Rose-John and J. Scheller (2008). "Transgenic blockade of 
interleukin 6 transsignaling abrogates inflammation." Blood 111(3): 1021-8. 
Rose-John, S. and P. C. Heinrich (1994). "Soluble receptors for cytokines and growth 
factors: generation and biological function." Biochem J 300 (Pt 2): 281-90. 
Rose-John, S., K. Mitsuyama, S. Matsumoto, W. M. Thaiss and J. Scheller (2009). 
"Interleukin-6 trans-signaling and colonic cancer associated with inflammatory 
bowel disease." Curr Pharm Des 15(18): 2095-103. 
Sahin, U. and C. P. Blobel (2007). "Ectodomain shedding of the EGF-receptor ligand 
epigen is mediated by ADAM17." FEBS Lett 581(1): 41-4. 
Sanderson, M. P., P. J. Dempsey and A. J. Dunbar (2006). "Control of ErbB signaling 
through metalloprotease mediated ectodomain shedding of EGF-like factors." 
Growth Factors 24(2): 121-36. 
Sanger, F., S. Nicklen and A. R. Coulson (1977). "DNA sequencing with chain-
terminating inhibitors." Proc Natl Acad Sci U S A 74(12): 5463-7. 
Scheller, J., J. Grötzinger and S. Rose-John (2006). "Updating interleukin-6 classic- 
and trans-signaling." Signal Transduction 6: 240-259. 
Schiemann, W. P., J. L. Bartoe and N. M. Nathanson (1997). "Box 3-independent 
signaling mechanisms are involved in leukemia inhibitory factor receptor 
alpha- and gp130-mediated stimulation of mitogen-activated protein kinase. 
Evidence for participation of multiple signaling pathways which converge at 
Ras." J Biol Chem 272(26): 16631-6. 
References 68 
Schmitz, J., M. Weissenbach, S. Haan, P. C. Heinrich and F. Schaper (2000). 
"SOCS3 exerts its inhibitory function on interleukin-6 signal transduction 
through the SHP2 recruitment site of gp130." J Biol Chem 275(17): 12848-56. 
Siegmund, B., H. A. Lehr, G. Fantuzzi and C. A. Dinarello (2001). "IL-1 beta -
converting enzyme (caspase-1) in intestinal inflammation." Proc Natl Acad Sci 
U S A 98(23): 13249-54. 
Sunnarborg, S. W., C. L. Hinkle, M. Stevenson, W. E. Russell, C. S. Raska, J. J. 
Peschon, B. J. Castner, M. J. Gerhart, R. J. Paxton, R. A. Black and D. C. Lee 
(2002). "Tumor necrosis factor-alpha converting enzyme (TACE) regulates 
epidermal growth factor receptor ligand availability." J Biol Chem 277(15): 
12838-45. 
Taga, T. and T. Kishimoto (1997). "Gp130 and the interleukin-6 family of cytokines." 
Annu Rev Immunol 15: 797-819. 
Thiel, S., H. Dahmen, A. Martens, G. Muller-Newen, F. Schaper, P. C. Heinrich and 
L. Graeve (1998). "Constitutive internalization and association with adaptor 
protein-2 of the interleukin-6 signal transducer gp130." FEBS Lett 441(2): 231-
4. 
Vollmer, P., I. Walev, S. Rose-John and S. Bhakdi (1996). "Novel pathogenic 
mechanism of microbial metalloproteinases: liberation of membrane-anchored 
molecules in biologically active form exemplified by studies with the human 
interleukin-6 receptor." Infect Immun 64(9): 3646-51. 
Walev, I., P. Vollmer, M. Palmer, S. Bhakdi and S. Rose-John (1996). "Pore-forming 
toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide." 
Proc Natl Acad Sci U S A 93(15): 7882-7. 
Walmsley, M., D. M. Butler, L. Marinova-Mutafchieva and M. Feldmann (1998). "An 
anti-inflammatory role for interleukin-11 in established murine collagen-
induced arthritis." Immunology 95(1): 31-7. 
Weskamp, G., K. Mendelson, S. Swendeman, S. Le Gall, Y. Ma, S. Lyman, A. 
Hinoki, S. Eguchi, V. Guaiquil, K. Horiuchi and C. P. Blobel (2010). 
"Pathological neovascularization is reduced by inactivation of ADAM17 in 
endothelial cells but not in pericytes." Circ Res 106(5): 932-40. 
Wirtz, S., C. Neufert, B. Weigmann and M. F. Neurath (2007). "Chemically induced 
mouse models of intestinal inflammation." Nat Protoc 2(3): 541-6. 
Xavier, R. J. and D. K. Podolsky (2007). "Unravelling the pathogenesis of 
inflammatory bowel disease." Nature 448(7152): 427-34. 
Yoshikawa, H., K. Takada and S. Muranishi (1984). "Molecular weight dependence of 
permselectivity to rat small intestinal blood-lymph barrier for exogenous 
macromolecules absorbed from lumen." J Pharmacobiodyn 7(1): 1-6. 
Zheng, X., F. Jiang, M. Katakowski, Z. G. Zhang, Q. E. Lu and M. Chopp (2009). 
"ADAM17 promotes breast cancer cell malignant phenotype through EGFR-
PI3K-AKT activation." Cancer Biol Ther 8(11): 1045-54. 
 
Appendices 69 
9  Appendices 






















Fig. 9-1: Vector maps of pCRScript-AP and pcDNA3.1. -AP-CD27.  
 










































































Coloured in green: AP-site, red: Flag-tag, blue: CD27, pink: His-tag and black: pcDNA3.1.  
 
9.3 Sequence of inserted Exon 11a in ADAM17 ex/ex mice 
E10 E11 E12ex E11aNeo
STOP
 
Fig. 9-2: Sequence of inserted Exon11a into ADAM17 gene. The artificial exon (highlighted in 
yellow) containing the stop codon is flanked by non-canonical plice donor and acceptor site.  
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